Anti-infective agents
A pharmaceutical composition with cetyltrimethylammonium halide and DTPA effectively addresses the challenge of treating multidrug-resistant fungal infections and disinfecting surfaces by utilizing a cationic surfactant, chelating agent, and solvent combination.
Patent Information
- Application Number
- JP2021505618
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-23
- Filing Date
- 2019-04-11
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2039-04-11
AI Technical Summary
Fungal infections, particularly those caused by multidrug-resistant fungi like Candida auris, are difficult to treat and often require specific antifungal drugs, posing a challenge for individuals with weakened immune systems or those taking medications such as antibiotics or corticosteroids.
A pharmaceutical composition comprising a cationic surfactant like cetyltrimethylammonium halide, a chelating agent like diethylenetriaminepentaacetic acid (DTPA) or its pharmaceutically acceptable salt, and a solvent is used in a unit dosage form to kill microorganisms, treat infections, disinfect surfaces, and sterilize produce.
The composition effectively kills a wide range of microorganisms, including multidrug-resistant fungi and bacteria, treats various infectious diseases, and disinfects or sterilizes surfaces and agricultural products, demonstrating broad-spectrum antimicrobial activity.
Smart Images

Figure 0007583705000018 
Figure 0007583705000019 
Figure 0007583705000020
Abstract
Description
[Technical field]
[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 62 / 656,111, filed April 11, 2018, and U.S. Provisional Application No. 62 / 749,309, filed October 23, 2018, each of which is incorporated by reference in its entirety. [Background technology]
[0002] Fungi are primitive organisms that live in the air, water, soil, and on other surfaces. Some fungi reproduce by dispersing spores through the air. When the spores attach to the body and grow, they can cause a fungal infection. People with weakened immune systems or those taking medications such as antibiotics or corticosteroids are at increased risk of fungal skin infections. Fungal infections are often difficult to treat and require antifungal drugs specific to the type of fungus causing the infection. Incorporation by Reference Each patent, publication, and non-patent literature cited in this application is incorporated by reference herein in its entirety, to the same extent as if each was individually incorporated by reference. Summary of the Invention
[0003] In some embodiments, the present disclosure provides a pharmaceutical composition comprising, in unit dosage form, a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) a solvent. In some embodiments, the disclosure provides a method of killing a microorganism, the method comprising administering to the microorganism a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. In some embodiments, the disclosure provides a method of treating an infectious disease, the method comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) a solvent. In some embodiments, the disclosure provides a method of disinfecting a surface, the method comprising dispensing a therapeutically effective amount of a pharmaceutical composition to a surface in need thereof, the pharmaceutical composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) a solvent. In some embodiments, the disclosure provides a method of sanitizing produce, the method comprising contacting the produce with an effective amount of a composition, the composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. [Brief description of the drawings]
[0004] [Figure 1] FIG. 1 shows that concentrated MM1 was effective in killing multidrug-resistant C. auris (ATCC 0385) at various dilution levels. [Diagram 2]Panel A of FIG. 2 shows the diameter (cm) of the Candida albicans clearing after treatment with MM1 (1), Derman® Antifungal Cream (1A), MM2 (2), and Equate® Athlete's Foot Antifungal Cream (2A). The bold circle encircles the diameter (cm) of the Candida albicans clearing after treatment with MM1. Panel B shows the diameter (cm) of the Candida albicans clearing after treatment with MM3 (3), Lotrimin® (3A), MM4 (4), and Tinactin® (4A). Panel C shows the diameter (cm) of the Candida albicans clearing after treatment with MM5 (5), Lamisil® (5A), MM6 (6), and Polymyxin B (PMB). [Diagram 3] FIG. 3 is a graph showing the clearance achieved by equal volumes of formulations MM1-MM6 against Candida albicans compared to equal volumes of commercially available Derman® antifungal cream, Equate® athlete's foot antifungal cream, Lotrimin® Ultra athlete's foot cream, Tinactin® athlete's foot cream, Lamisil® athlete's foot cream, and polymyxin B. [Figure 4] Panel A of Figure 4 shows the residual protection of MM1 and MM1 at a 1:1000 dilution against Candida albicans on a moist agar surface. Panel B shows the protection of MM1 and MM1 at a 1:1000 dilution against Candida albicans on a moist agar surface without prior treatment with MM1. Panel B shows that treatment with MM1 and MM1 at 1:1000 resulted in the quenching of pre-existing Candida albicans infection. [Diagram 5]Panel A of FIG. 5 shows the diameter (cm) of a clearing of Trichophyton rubrum when treated with MM1 (1), Derman® Antifungal Cream (1A), MM2 (2), or Equate® Athlete's Foot Antifungal Cream (2A). Panel B shows the diameter (cm) of a clearing of Trichophyton rubrum when treated with MM3 (3), Lotrimin® Ultra Athlete's Foot Cream (3A), MM4 (4), or Tinactin® Athlete's Foot Cream (4A). Panel C shows the diameter (cm) of a clearing of Trichophyton rubrum when treated with MM5 (5), Lamisil® Athlete's Foot Cream (5A), MM6 (6), or Polymyxin B (PMB). The left panel of Panel D shows a magnified image of the circle shown in Panel C. The right panel of Panel D shows a magnified image of the circle shown in Panel B. [Figure 6] FIG. 6 shows the comparative efficacy of MM1-MM6 and the commercial formulation in killing T. rubrum after 12 and 24 days of treatment. [Figure 7] Panel A of Figure 7 shows the diameter (cm) of T. rubrum clearing after 12 days of treatment with MM1, Derman® (1), Equate® Athlete's Foot (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the diameter (cm) of T. rubrum clearing after 12 days of treatment with MM1, Tinactin® Athlete's Foot Cream (4), and Lamisil® Athlete's Foot Cream (5). Panel C shows the diameter (cm) of T. rubrum clearing after 30 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot (2), and Lotrimin® Ultra Athlete's Foot Cream (3). Panel D shows the diameter (cm) of the clearing ring of T. rubrum after 30 days of treatment with MM1, Tinactin® athlete's foot cream, and Lamisil® athlete's foot cream. [Figure 8]Figure 8 shows the comparative effectiveness of the formulations in killing T. rubrum. The data shows that MM1 was more effective than Derman® Antifungal Cream, Equate® Athlete's Foot, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream in killing T. rubrum 12 days after application and 30 days after application. [Figure 9] Panels A-G of Figure 9 show images of untreated wood samples infected with Aspergillus niger, and panel HM shows images of Aspergillus niger infected wood samples treated with MM1. [Figure 10] Panel A of Figure 10 shows an MHA plate wiped with a wood sample treated with MM1 after 2 days, Panel B shows an MHA plate wiped with an untreated wood sample after 2 days, Panel C shows an MHA plate wiped with a wood sample treated with MM1 after 5 days, and Panel D shows an MHA plate wiped with an untreated wood sample after 5 days. [Figure 11] Panel A of Figure 11 shows the front side of an MHA plate infected with A. niger treated with MM1 and Lamisil® Ultra Athlete's Foot Cream after 5 days of incubation, and Panel B shows the back side of an MHA plate infected with A. niger treated with MM1 and Lamisil® Ultra Athlete's Foot Cream after 5 days of incubation. [Figure 12] FIG. 12 shows a comparison of spot spread diameter (cm) of MHA plates infected with A. niger treated with MM1 and Lamisil® Ultra Athlete's Foot Cream. [Figure 13] Panel A of Figure 13 shows the front side of an MHA plate infected with A. niger treated with MM1 and Lamisil® Ultra Athlete's Foot Cream after a 32 day incubation time, and Panel B shows the back side of an MHA plate infected with A. niger treated with MM1 and Lamisil® Ultra Athlete's Foot Cream after a 32 day incubation time. [Figure 14]Panel A of Figure 14 shows a 6-well plate with three wells pre-treated with MM1 and three wells pre-treated with MHB control. The upper panel of panel B shows an MHA plate treated with MHB, inoculated with A. niger and wiped with wells treated with MHB. The lower panel of panel B shows an MHA plate pre-treated with MHB, inoculated with A. niger and wiped with wells treated with MM1. Panel C shows the 6-well plate after 7 days of incubation. [Figure 15] Panel A of FIG. 15 shows the degree of clearing of drug-resistant Candida parapsilosis after 1 day of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the degree of clearing of drug-resistant Candida parapsilosis after 1 day of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C shows the degree of clearing of drug-resistant Candida parapsilosis after 15 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D shows the extent of clearing of drug-resistant Candida parapsilosis after 15 days of treatment with MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5). [Figure 16] FIG. 16 shows the comparative efficacy of MM1 and the commercial formulation in killing drug-resistant Candida parapsilosis after 1 and 15 days of treatment. [Figure 17]Panel A of FIG. 17 shows the diameter (cm) of a clearing of drug-resistant Candida auris (CDC 0383) after 1 day of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the diameter (cm) of a clearing of drug-resistant Candida auris (CDC 0383) after 1 day of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C shows the diameter (cm) of a clearing of drug-resistant Candida auris (CDC 0383) after 15 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D shows the diameter (cm) of clearing rings of drug-resistant Candida auris (CDC 0383) after 15 days of treatment with MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5). [Figure 18] FIG. 18 shows the comparative efficacy of MM1 and a commercial formulation in killing drug-resistant Candida auris (CDC 0383) after 1 and 15 days of treatment. [Figure 19] Panel A of Figure 19 shows the diameter (cm) of clearing of drug-resistant Candida auris (CDC 0383) when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the diameter (cm) of clearing of drug-resistant Candida auris (CDC 0383) when treated with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). [Figure 20] FIG. 20 shows the comparative efficacy of MM1 and a commercial formulation in killing drug-resistant Candida auris (CDC 0383). [Figure 21]Panel A of FIG. 21 shows the diameter (cm) of a clearing of multi-resistant Candida auris (CDC 0385) after 1 day of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the diameter (cm) of a clearing of multi-resistant Candida auris (CDC 0385) after 1 day of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C shows the diameter (cm) of a clearing of multi-resistant Candida auris (CDC 0385) after 15 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D shows the diameter (cm) of clearing rings of multidrug-resistant Candida auris (CDC 0385) after 15 days of treatment with MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5). [Figure 22] FIG. 22 shows the comparative efficacy of MM1 and a commercial formulation in killing multi-drug resistant Candida auris (CDC 0385) after 1 or 15 days of treatment. [Figure 23] FIG. 23 shows the comparative efficacy of the Monistat® 3 complete line, MM1 formulated in PBS, and MM1 formulated in PG in killing multidrug resistant Candida auris (CDC 0385). [Figure 24] FIG. 24 shows a 12-well plate used to simulate the use of MM1 as a mouthwash and douche. [Diagram 25]FIG. 25 shows the results for 1) wells pre-treated with MM1 and inoculated with multidrug-resistant Candida auris (CDC 0385), 2) wells pre-treated with MHB and inoculated with multidrug-resistant Candida auris (CDC 0385), 3) wells inoculated with multidrug-resistant Candida auris (CDC 0385) and treated with MM1, and 4) wells inoculated with multidrug-resistant Candida auris (CDC 0385) and treated with MHB. [Figure 26] FIG. 26 shows the comparative effect of MM1 and MHB controls on the growth of multidrug-resistant Candida auris (CDC 0385) when applied to a surface prior to inoculation with multidrug-resistant Candida auris (CDC 0385) (black) or when applied to a surface after the surface is inoculated with multidrug-resistant Candida auris (CDC 0385). [Figure 27] Panel A of FIG. 27 shows the clearing of Candida krusei (CDC 0397) after 1 day when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B shows the clearing of Candida krusei (CDC 0397) after 1 day when treated with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C shows the clearing of Candida krusei (CDC 0397) after 15 days when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D shows clearing of Candida krusei (CDC 0397) after 15 days when treated with a single dose of MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5). [Figure 28] FIG. 28 shows the comparative efficacy of MM1 and a commercial formulation in killing Candida krusei (CDC 0397). [Figure 29]FIG. 29 shows the 12-well plate used to treat an unidentified plant fungus with MM1. [Diagram 30] Panel A of Figure 30 shows a 6-well plate after 2 days of incubation in which two wells were pre-treated with MM1 and then not washed, two wells were pre-treated with MM1 and then washed with MHB to remove the residual MM1, or two wells were washed with MHB only to serve as positive growth controls. Panel B shows the unidentified plant fungus used in the residual protection assay. Panel C shows a 6-well plate after 7 days of incubation in which four wells were pre-treated with MM1 and two wells were pre-treated with MHB controls. [Diagram 31] Panel A of Figure 31 shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill MRSA (BAA-44). Panel B shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill Acinetobacter baumannii (ATCC 1797). Panel C shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill Pseudomonas aeruginosa (ATCC 2114). Panel D shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill multidrug-resistant Candida auris (CDC 0385). [Diagram 32] FIG. 32 shows the toxicity of chlorhexidine gluconate 0.12% mouthwash to HeLa cells. [Diagram 33] Figure 33 shows the toxicity of MM8 to HeLa cells. MM8 had an IC50 (GI50) of the compound of 0.22% v / v. [Diagram 34]Panel A of Figure 34 shows that wells treated with water showed no protection from C. albicans, while wells treated with MM8 showed residual protection. The top right panel of panel B shows that wells pre-treated with MM8 and inoculated with C. albicans showed residual protection from the fungus. The bottom left panel of panel B shows that MHA plates infected with C. albicans treated with water showed no protection against the fungus. The bottom right panel of panel B shows that MHA plates infected with C. albicans treated with MM8 showed protection against the fungus. Panel C shows that MHA plates infected with C. auris treated with MM8 showed protection against C. auris. [Diagram 35] Panel A of Figure 35 shows that MM8 and Monistat® 3 killed Candida albicans, but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Candida albicans. Panel B shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems when used to treat Candida albicans. [Diagram 36] FIG. 36 shows that treatment with the Monistat® 3 complete system resulted in colony invasion at the edge of the clearance diameter, resulting in a smaller clearance diameter than MM8. [Figure 37]Panel A of Figure 37 shows that MM8 and Monistat® 3 killed multi-resistant Candida auris (CDC 0385), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida auris (CDC 0385). Panel B shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems when used to treat multi-resistant Candida auris (CDC 0385). [Figure 38] Panel A of Figure 38 shows that MM8 and Monistat® 3 killed Candida krusei (CDC 0397), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida krusei (CDC 0397). Panel B shows a comparison of clearance diameter (mm) when used to treat multi-resistant Candida auris (CDC 0385) in MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Systems. [Figure 39] FIG. 39 shows that treatment with the Monistat® 3 complete system resulted in colony invasion at the edge of the clearance diameter, resulting in a smaller clearance diameter than MM8. [Diagram 40]Panel A of Figure 40 shows that MM8 and Monistat® 3 Complete System killed Candida glabrata (CDC 0315), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida glabrata (CDC 0315). Panel B shows a comparison of clearance diameter (mm) when used to treat multi-resistant Candida glabrata (CDC 0315) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System. [Diagram 41] Panel A of Figure 41 shows that MM8 and Monistat® 3 Complete System killed Candida haemulonii (CDC 0393), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida haemulonii (CDC 0393). Panel B of Figure 41 shows a comparison of the clearance diameter (mm) when used to treat multi-resistant Candida haemulonii (CDC 0393) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System. [Diagram 42]Panel A of Figure 42 shows that MM8, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System killed Candida duobshaemulonii (CDC 0394), but Lotrimin® Ultra Athlete's Foot Cream and Tinactin® Athlete's Foot Cream did not kill Candida duobshaemulonii (CDC 0394). Panel B shows a comparison of clearance diameter (mm) when used to treat Candida duobshaemulonii (CDC 0394) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System. [Diagram 43] Panel A of Figure 43 shows that MM8 and Monistat® 3 Complete System killed Candida tropicalis (CDC 0345), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Candida tropicalis (CDC 0345). Panel B shows a comparison of the clearance diameter (mm) when used to treat Candida tropicalis (CDC 0345) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System. [Diagram 44] FIG. 44 shows that treatment with the Monistat® 3 complete system resulted in colony invasion at the edge of the clearance diameter, resulting in a clearance diameter of zero mm. [Diagram 45]Panel A of Figure 45 shows that MM8, Lamisil® Athlete's Foot Cream, and Derman® Antifungal Cream killed Aspergillus niger, while Lotrimin® Ultra Athlete's Foot Cream and Tinactin® Athlete's Foot Cream did not. Panel B shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Derman® Antifungal Cream when used to treat Aspergillus niger. [Figure 46] Panel A of Figure 46 shows that MM8 and Monistat® 3 killed Cryptococcus neoformans (H99), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Cryptococcus neoformans (H99). Panel B shows a comparison of the clearance diameter (mm) used to treat Cryptococcus neoformans (H99) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems. [Figure 47]Panel A of Figure 47 shows that MM8 and Monistat® 3 Complete System killed Cryptococcus gattii (K265), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Cryptococcus gattii (K265). Panel B shows a comparison of the clearance diameter (mm) when used to treat Cryptococcus gattii (K265) for MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System. [Figure 48] Figure 48 shows that MM8 killed Geomyces destructans. [Figure 49] Panel A of Figure 49 shows that MM8, Lamisil® Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Derman® Antifungal Cream killed T. rubrum. Lamisil® Athlete's Foot Cream was the most effective at killing T. rubrum. Panel B shows that MM8 was as effective as chlorhexidine gluconate 0.12% mouthwash at killing T. rubrum. [Figure 50] Panel A of Figure 50 shows circles encircling the diameter of clearance produced by treatment with MM8, demonstrating that mupirocin and neomycin were more effective than MM8, but MM8 was more effective than bacitracin and triple antibiotic ointment after a 1 day incubation period. Panel B shows that MM8 and chlorhexidine gluconate 0.12% mouthwash were approximately equally toxic against Yesenia pestis (Kimo 6). [Figure 51]Panel A of Figure 51 shows that MM8 and bacitracin killed VRE after a one day incubation time. The circles enclose the clearance diameter created by treatment with MM8, showing that MM8 was the most effective treatment compared to mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Panel B shows that after seven days of incubation, the area of VRE treated with MM8 was only the clearance diameter remaining, indicating that one treatment with MM8 had a long-lasting effect on VRE. [Figure 52] Panel A of Figure 52 shows that MM8 and mupirocin killed MRSA after one day of incubation time, and Panel B shows that after four days of incubation, MM8 and mupirocin was the best formulation that killed VRSA. [Figure 53] Panel A of Figure 53 shows that MM8 and mupirocin killed CRE NDM-1 MDR after one day of incubation. Panel B shows that after five days of incubation, MM8 and mupirocin were the best formulations that killed CRE NDM-1 MDR. [Figure 54] FIG. 54 shows that MM8 and mupirocin killed A. baumannii after a 1-day incubation period. [Figure 55] FIG. 55 shows that MM8 and mupirocin killed multidrug-resistant P. aeruginosa after a 1-day incubation period. [Figure 56] Panel A of Figure 56 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed Escherichia coli (O157:H7) after one day of incubation. Panel B shows that after five days of incubation, MM8, mupirocin, neomycin, and triple antibiotic ointment were the best formulations that killed E. coli (O157:H7). [Figure 57]Panel A of Figure 57 shows that MM8 was the only formulation that killed multidrug-resistant Burkholderia cepacia after one day of incubation. Panel B shows that after four days of incubation, MM8 was the only formulation that killed multidrug-resistant Burkholderia cepacia. [Figure 58] Panel A of Figure 58 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed Streptococcus pyogenes after one day of incubation time. Panel B shows that after seven days of incubation, MM8, mupirocin, neomycin, and triple antibiotic ointment further killed S. pyogenes. [Figure 59] FIG. 59 shows that S. pyogenes colonies invaded the neomycin and triple antibiotic treated areas, while the MM8 treated areas showed no regrowth of S. pyogenes colonies. [Figure 60] FIG. 60 shows that MM8 killed polymyxin E resistant Stenotrophomonas maltophilia after 1 day incubation time. [Figure 61] FIG. 61 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed Bacillus subtilis after a one day incubation period. [Figure 62] Panel A of Figure 62 shows that MM8 was the only formulation that killed Mycobacterium abscessus. Panel B shows the image of MHA stained with MTT. [Figure 63] Panel A of Figure 63 shows that MM8 and mupirocin killed MRSA BAA-1717 (USA 300). Panel B shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed multidrug-resistant Burkholderia cepacia. [Figure 64] Panel A of Figure 64 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed MRSA BAA-1717 (USA 300). Panel B shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed MRSA BAA-44. [Figure 65] Panel A of Figure 65 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Acinetobacter baumannii (ATCC 1797). Panel B shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Pseudomonas aeruginosa (ATCC 2114). [Figure 66] Panel A of Figure 66 shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed multidrug-resistant Burkholderia cepacia. Panel B shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed multidrug-resistant Candida auris. [Figure 67] Panel A of Figure 67 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida albicans (ATCC 26555). Panel B shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida auris (CDC 0383) after a 2-day incubation period. [Figure 68] Panel A of Figure 68 shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed Candida tropicalis (CDC 0345) after a 2-day incubation period. Panel B shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed Candida glabrata (CDC 0315) after a 2-day incubation period. [Figure 69]Panel A of Figure 69 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Candida haemulonii (CDC 0393) after a 2-day incubation period. Panel B shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Candida duobushaemulonii (CDC 0339) after a 2-day incubation period. [Figure 70] Panel A of Figure 70 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida parapsilosis (CDC 0339) after a 2-day incubation period. Panel B shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida krusei (CDC 0397) after a 2-day incubation period. [Figure 71] Panel A of Figure 71 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Cryptococcus gattii. Panel B shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Cryptococcus neoformans. [Figure 72] Panel A of Figure 72 shows the front side of an MHA plate infected with A. niger and demonstrates that MM8 and a 0.12% chlorhexidine gluconate rinse killed A. niger. Panel B shows the back side of an MHA plate infected with A. niger and demonstrates that MM8 and a 0.12% chlorhexidine gluconate rinse killed A. niger. [Figure 73] FIG. 73 shows that chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8 were equally effective on pre-established Staphylococcus epidermis biofilms after 15 minutes of treatment. [Figure 74]Panel A of Figure 74 shows the colorimetric results of treating 8-day-old Candida auris biofilms with PAO, no treatment, chlorhexidine gluconate 0.12% mouthwash, MM7, or MM8. Panel B shows that chlorhexidine gluconate 0.12% mouthwash, MM7, and MM8 were most effective at killing pre-established multidrug-resistant Candida auris biofilms. [Figure 75] Panel A of Figure 75 shows the colorimetric results of treating 6-day-old Candida albicans biofilms with PAO, no treatment, chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8. Panel B shows that chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8 were the most effective at killing pre-established multidrug-resistant Candida albicans biofilms. [Figure 76] Panel A of Figure 76 shows chicken skin samples infected with B. subtilis and disinfected with concentrated MM8. Panel B shows colony counts after treatment with water (top) and 5x concentrated MM8 (bottom). Panel C shows colony counts after treatment with water (top) or 2x concentrated MM8 (bottom). Panel D shows colony counts after treatment with water (top) or 1x MM8 (bottom). [Figure 77] Panel A of Figure 77 shows that 20% FBS did not reduce the efficacy of MM8 or chlorhexidine gluconate 0.12% mouthwash on gram-positive MRSA. Panel B shows that 20% FBS did not reduce the killing efficiency of MM8 on gram-negative multidrug-resistant A. baumannii, but 20% FBS reduced the efficacy of chlorhexidine gluconate 0.12% mouthwash on multidrug-resistant A. baumannii. [Figure 78] Panel A of Figure 78 shows that MM810 was less effective than MM8 alone at killing Acinetobacter baumannii (ATCC 1797). Panel B shows that MM810 was less effective than MM8 alone at killing MRSA BAA-44. [Figure 79]Panel A of Figure 79 shows that MM810 was more effective than MM8 alone at killing multidrug-resistant Candida auris. Panel B shows that MM8100 was more effective than MM8 alone at killing multidrug-resistant Candida auris. [Figure 80] Panel A of Figure 80 shows that MM8100 was more effective than MM8 alone at killing P. aeruginosa (ATCC 2114). Panel B shows that MM8100 was more effective than MM8 alone at killing MMRSA BAA-44. [Figure 81] FIG. 81 shows that MM8100 was more effective than MM8 alone in killing Burkholderia cepacia (ATCC 10856). [Figure 82] FIG. 82 shows that CellLytic® B produced dramatic clearance, whereas chlorhexidine gluconate 0.12% rinse and MM8 had no effect on plate color. [Figure 83] Panel A of Figure 83 shows that MM8, a 1:2 aqueous dilution of MM8, and a 1:10 aqueous dilution of MM1 were equally effective at killing the anaerobic bacterium Propionibacterium acnes (ATCC 6919). Panel B shows that MM8, a 1:2 aqueous dilution of MM8, and a 1:10 aqueous dilution of MM1 were equally effective at killing Streptococcus mutans (85W 2357). [Figure 84] FIG. 84 shows blood agar plates spotted with cell lysis buffer, MM7, 4% benzoyl peroxide, 10% benzoyl peroxide, and 2% salicylic acid. [Figure 85]Panel A of Figure 85 shows MHA plates of MRSA BAA-44 treated with MM7, MM8, MM12, MM13, and a vehicle control. Panel B shows MHA plates of A. baumannii treated with MM7, MM8, MM12, MM13, and a vehicle control. Panel C shows MHA plates of P. aeruginosa treated with MM7, MM8, MM12, MM13, and a vehicle control. Panel D shows MHA plates of C. albicans treated with MM7, MM8, MM12, MM13, and a vehicle control. [Figure 86] Panel A of Figure 86 shows MHA plates of A. baumannii treated with MM7, MM9, MM10, and MM11. Panel B shows MHA plates of MRSA BAA-44 treated with MM7, MM9, MM10, and MM11. Panel C shows MHA plates of P. aeruginosa treated with MM7, MM9, MM10, and MM11. Panel D shows MHA plates of C. albicans treated with MM7, MM9, MM10, and MM11. [Figure 87] Panel A of Figure 87 shows MHA plates of MRSA BAA-44 treated with MM7, MM9, MM10, and MM11. Panel B shows MHA plates of A. baumannii (ATCC 1797) treated with MM7, MM9, MM10, and MM11. Panel C shows MHA plates of P. aeruginosa (ATCC 2114) treated with MM7, MM9, MM10, and MM11. Panel D shows MHA plates of C. albicans treated with MM7, MM9, MM10, and MM11. [Figure 88] FIG. 88 shows MHA plates of MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotic treated E. coli (AR 0350). [Figure 89] FIG. 89 shows MHA plates of multi-drug resistant E. coli (AR 0348) treated with MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotic cream. [Figure 90]FIG. 90 shows MHA plates of multi-drug resistant E. coli (AR 0346) treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic cream. [Figure 91] FIG. 91 shows the effect of a MM12 / petroleum jelly mixture (VaselineMD) and Vaseline on killing lawns infected with A. baumannii ATCC 1797, MRSA BAA-44, and C. albicans. [Figure 92] FIG. 92 shows that MM14 delivered in water or propylene glycol (PG) was effective in killing Proteus mirabilis. [Figure 93] Figure 93 shows that MM14 delivered in water was effective in killing S. mutans. [Figure 94] Figure 94 shows that MM14 delivered in water was effective in killing Propionibacterium acnes. [Figure 95] FIG. 95 shows that MM14 was effective in killing Salmonella enteriditis, Shigella flexneri, Streptococcus pyogenes, Burkholderia cepacia, Clostridium spp., and Yersinia pestis. [Figure 96] FIG. 96 shows that MM14 and MM18 were effective in killing Xanthomonas campestris (ATCC 19155) and Clavibacter sp. (ATCC 43179). [Figure 97] FIG. 97 shows that MM14 kills Clavibacter spp. in 30 seconds of exposure. [Figure 98]FIG. 98 shows the efficacy of MM18 powder against A. baumannii ATCC 1997. [Figure 99] FIG. 99 shows the anti-infective properties of MM14 in combination with other agents. [Figure 100] FIG. 100 shows that pretreatment of seeds with MM14 or MM18 does not affect seed germination efficiency. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0005] Fungi are primitive organisms that live in the air, water, soil, and on other surfaces. Some fungi reproduce by releasing spores through the air. When the spores attach to the body and grow, they can cause a fungal infection. People with weakened immune systems or who take medications such as antibiotics or corticosteroids are at increased risk of fungal skin infections. Fungal infections are often difficult to treat. Treatment often involves topical or oral medications. The type of antifungal drug used to treat the infection depends on the specific species of fungus causing the infection.
[0006] application The present disclosure describes antifungal formulations that can be used to treat fungal infections. For example, the formulations of the present disclosure can treat Candida auris (C. auris), cryptococcal meningitis, fungal eye infections, oral candidiasis, vaginal candidiasis, candidal vaginitis, tinea pedis (athlete's foot), pulmonary aspergillosis, chronic pulmonary aspergillosis, Trichophyton rubrum-infected toenails and fingernails, tinea capitis (tinea capitis), ringworm, mucormycosis, or blastomycosis. The formulations of the present disclosure can also be used to treat infections caused by fungi of the phylum Ascomycetous (e.g., the subphylum pezizomycotina, saccharomycotina, and taphrinomycotina), Trichophyton, epidermophyton, microsporum, Aspergillus, Blastomyces, Cryptococcus neoformans, Cryptococcus gattii, Trichophyton rubrum, Aspergillus niger, stachybotrys, Batrachochytrium dendrobatidis (frog Bd fungus), or Blastomyces dermatitidis.
[0007] C. auris is a yeast-like fungus related to Candida albicans. C. auris is one of a few species of the genus Candida that can cause candidiasis in humans. Candidiasis can be acquired in hospitals by patients with weakened immune systems. C. auris can cause invasive candidiasis in which the bloodstream (fungemia), central nervous system, and internal organs are affected. C. auris is likely to be misidentified as other Candida species. The fungus causes invasive infections with a high mortality rate (about 57%), mainly bloodstream, wound, and ear infections. In contrast to other fungal diseases, C. auris is invasive and multidrug resistant, and is usually associated with outbreaks in healthcare settings such as hospitals. Meningitis, an infection of the lining of the spinal cord and brain, is the most common illness caused by cryptococcus. Cryptococcal meningitis can cause coma and death, and can also affect the skin, lungs, or other parts of the body. The risk of cryptococcal infection is highest when a person's CD4 count is below 100. Cryptococcal meningitis is the major HIV-associated opportunistic infection.
[0008] Fungal eye infections are rare, but can be very serious. The most common reason a person develops a fungal eye infection is an injury to the eye, especially one caused by plant material such as a twig or thorn. Inflammation or infection of the cornea is called keratitis, and inflammation or infection inside the eye is called endophthalmitis. In some embodiments, the fungal eye infection is caused by Moniliaceae, Dematiaceae, and yeast. Moniliaceae includes non-pigmented filamentous fungi such as Fusarium and Aspergillus species, Dematiaceae includes pigmented filamentous fungi such as Curvularia and Lasiodiplodia species, and yeast includes Candida species.
[0009] Cryptococcus neoformans and Cryptococcus gattii are species of fungi that can cause cryptococcosis, also known as cryptococcosis. Cryptococcus is a potentially fatal fungal disease that can be contracted by inhaling infectious propagules from the environment. Cryptococcus does not spread from person to person. Chytrid fungus is a species of fungus that can cause chytridiomycosis in amphibians such as frogs. It can be introduced into amphibians through water exposure, which can ultimately lead to cardiac arrest and death.
[0010] The formulations of the present disclosure can be used as treatments against bacterial pathogens. Non-limiting examples of bacterial pathogens that can be treated with the formulations of the present disclosure include Bacillus anthracis (anthrax), Franscisella tularensis (tularemia), Yersinia pestis (plague), Clostridium botulinum (botulism), Coxiella burnetti (Q fever), Brucella species (brucellosis), Burkholderia mallei (glanders), Clostridium perfringens (clostridial necrotizing enteritis), Vibrio cholerae (cholera), and Porphyromonas gingivalis (gingivitis, and can cause Alzheimer's disease).
[0011] The formulation of the present disclosure can be used as a treatment against viral pathogens.Non-limiting examples of viral pathogens that can be treated with the formulation of the present disclosure include, for example, arenaviruses, such as Lassa fever virus, Junin mammarenavirus, and Machupo virus; filoviruses, such as Ebola virus, and Marburg virus; soybean pox (smallpox); Nipah virus; Hantavirus; Nairovirus (Bunyaviridae); lentiviruses, such as HIV; Varicella zoster virus; Paramyxovirus; Measles virus; Rhinovirus; Coronavirus; Respiratory syncytial virus; Influenza virus; Norovirus; Hepatitis A; Rotavirus; Astrovirus; and Norwalk-like virus. The formulations of the present disclosure can be used as treatments against plant pathogens such as Xanthomonas campestris and Clavibacter spp. Xanthomonas campestris is a black spot disease that can affect cruciferous vegetables and other plants. Clavibacter spp. is a bacterial canker disease of tomato / potato plants. Infection with Clavibacter spp. can begin in the seed, and infected seeds may be indistinguishable from healthy seeds.
[0012] The formulations of the present disclosure can be used to treat human skin, animal skin, wounds, and body cavities, such as the mouth, vagina, ear, or nose. The formulations of the present disclosure can also be used to treat infected surfaces, such as wood, metal, glass, concrete, painted surfaces, or plastic surfaces. The formulations of the present disclosure can be used to treat surfaces made of porous or non-porous materials. In some embodiments, the surface can include horizontally or vertically aligned non-porous substrates, such as floors and walls, countertops, tabletops, medical equipment, gurneys, cardiac stress test chamber surfaces, toilets, or seats. In some embodiments, the formulations of the present disclosure can be used to treat complex three-dimensional structures, such as faucets, tools, or other equipment. In some embodiments, the formulations of the present disclosure can be used to treat and disinfect vehicle cabins, buildings, medical equipment, manufactured products, buildings and infrastructure for demolition, military assets, aircraft, military vessels, or civilian vessels.
[0013] The formulations of the present disclosure can be used to treat agricultural products such as seeds, plants, or crops. In some embodiments, the formulations of the present disclosure can be used to treat rice seeds, rice plants, barley seeds, barley plants, flax seeds, flax plants, sorghum seeds, sorghum plants, tomato seeds, tomato plants, potato tubers, potatoes, mustard seeds, mustard plants, collard seeds, collard plants, rutabaga seeds, rutabagas, turnip seeds, turnips, cabbage seeds, cabbage plants, broccoli seeds, broccoli, cauliflower seeds, cauliflowers, Brussels sprout seeds, Brussels sprouts, radish seeds, radishes, kale seeds, It can be used to treat kale, turfgrass seed, turfgrass, banana seed, banana plant, tangerine seed, tangerine plant, orange seed, orange tree, apple seed, apple tree, strawberry seed, strawberry plant, blueberry seed, blueberry plant, melon seed, melon plant, cantaloupe seed, cantaloupe plant, watermelon seed, watermelon plant, papaya seed, papaya plant, pea seed, pea plant, corn seed, corn stalk, wheat seed, wheat, sugar cane, sugar cane seed, or beans.
[0014] Pharmaceutical Compositions of the Invention The pharmaceutical composition of the present disclosure comprises a cationic surfactant, a chelating agent, and at least one solvent.For example, the pharmaceutical composition of the present disclosure can comprise a cationic surfactant, such as a pH-dependent primary, secondary, or tertiary amine.In some embodiments, the pharmaceutical composition of the present disclosure can comprise octenidine dihydrochloride.The pharmaceutical composition of the present disclosure can also comprise a permanently charged quaternary ammonium salt, such as cetyltrimethylammonium bromide (CTAB), cetyltrimethylammonium chloride (CTAC), benzylalkonium chloride (BAC), benzethonium chloride (BZT), dimethyldioctadecylammonium chloride, or dioctadecyldimethylammonium bromide (DODAB). The pharmaceutical compositions of the invention can be used, for example, before, during, or after treatment of a subject with a second pharmaceutical agent.
[0015] The pharmaceutical composition of the present invention may be a combination of the pharmaceutical compound described herein with other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. The pharmaceutical composition facilitates the administration of the compound to an organism. The pharmaceutical composition may be administered in a therapeutically effective amount as a pharmaceutical composition by various forms and routes, including, for example, intraocular, intranasal, intravaginal, and topical administration.
[0016] For oral administration, pharmaceutical compositions can be formulated by combining active compounds with pharma- ceutically acceptable carriers or excipients. Such carriers can be used to prepare liquids, gels, syrups, elixirs, slurries, or suspensions for use as mouthwash by subjects. Non-limiting examples of solvents used in oral dissolvable formulations include water, ethanol, isopropanol, saline, saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate-buffered saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), and saline citrate sodium buffer (SSC). Non-limiting examples of co-solvents used in oral dissolvable formulations can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.
[0017] The formulations of the present disclosure may include chelating agents such as ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid, or cyclohexanediaminetetraacetic acid. The chelating agents of the formulations of the present disclosure may be, for example, Prussian blue, citric acid, peptides, amino acids, such as short chain amino acids, aminopolycarboxylic acids, gluconic acid, glucoheptonic acid, organic phosphonic acid compounds, bisphosphonates (e.g., pamidronate), or inorganic polyphosphates. In some embodiments, the sodium, calcium, or zinc salt of DTPA may be used as a chelating agent.
[0018] The formulations of the present disclosure may include surfactants, such as one or more alkanolamines, alkylarylsulfonates, amine oxides, poly(oxyalkylene) compounds (e.g., block copolymers containing alkylene oxide repeat units), carboxylated alcohol ethoxylates, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated amines and amides, ethoxylated fatty acids, ethoxylated fatty acid esters and oils, fatty acid esters, fatty acid amides, glycerol esters, glycol esters, sorbitan esters, imidazoline derivatives, lechithins, and The surfactants may include lecithin derivatives, lignin and lignin derivatives, monoglycerides and monoglyceride derivatives, olefin sulfonates, phosphate esters and derivatives, propoxylated and ethoxylated fatty acids or alcohols or alkylphenols, sorbitan derivatives, sucrose esters and derivatives, sulfates or alcohols or ethoxylated alcohols or fatty acid esters, dodecyl and tridecylbenzene or condensed naphthalene or petroleum sulfates or sulfonates, sulfosuccinates and derivatives, or tridecyl and dodecylbenzene sulfonic acid. In some embodiments, the formulations of the present disclosure may include more than one surfactant. In some embodiments, the formulations of the present disclosure may include sodium dodecyl sulfate (SDS), sodium lauryl sulfate, cetrimonium cation, cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, hexadecyltrimethylammonium bromide, hexadecyltrimethylammonium chloride, or combinations thereof.
[0019] The formulations of the present disclosure may also include a solvent or mixture of solvents, such as propylene glycol (PG), dimethyl sulfoxide (DMSO), Ficoll® 400 (e.g., 7.5% w / v final), low molecular weight methylcellulose, methanol, ethanol, polyvinyl alcohol, isocetyl alcohol, oleyl alcohol, or propanol. In some embodiments, the formulations of the present disclosure may include a solvent or mixture of solvents, such as polyethylene glycol, water, glycerol, aloe extract, paraffin oil, petroleum gel, petrolatum, acetylated lanolin alcohol, almond oil, apricot kernel oil, avocado oil, cocoa butter, coconut butter, corn oil, cottonseed oil, evening primrose oil, hydrogenated vegetable oil, isodecyl oleate, jojoba oil, olive oil, peanut oil, PEG8 castor oil, sandalwood seed oil, sesame oil, shark liver oil, soybean oil, or sulfated jojoba oil.
[0020] The formulations of the present disclosure may also contain additional non-comodogenic or comodogenic ingredients, such as colloidal silicon dioxide, beeswax, butyl stearate, capric acid, caprylic acid, carnauba wax, etc. wax), ceteareth 20, cetyl acetate, cetyl alcohol, cetearyl alcohol, D&C Red #17, D&C Red #19, D&C Red #21, D&C Red #27, D&C Red #3, D&C Red #30, D&C Red #33, D&C Red #36, D&C Red #4, D&C Red #40, D&C Red #9, decyl oleate, di(2-ethylhexyl) succinate, dimethicone, dioctyl malate, dioctyl succinate, eicosanoic acid, ethylhexyl palmitate, ethylhexyl pelargonate, glyceryl tricaprylo / caprate, glyceryl stearate NSE, Glyceryl Stearate SE, Glyceryl-3-Diisostearate, Hexylene Glycol, Isocetyl Alcohol, Isodecyl Oleate, Isopropyl Isostearate, Isopropyl Linolate, Isopropyl Myristate, Isopropyl Palmitate, Isostearyl Isostearate, Isostearyl Neopentanoate, Lanolin Wax, Laureth-23, Laureth-4, Lauric Acid, Mink Oil, Myristic Acid, Myristyl Lactate, Myristyl Myristate, Myristyl Alcohol, Oleth-10, Oleth-20, Oleth-3, Oleth-3 Phosphate, Oleth-5, Oleyl Alcohol, Palmitic Acid, PEG-40 100 Distearate, PEG 150 Distearate, PEG 16 Lanolin (Solulan 16), PEG 20 Stearate, PEG 200 Dilaurate, PEG 8 Castor Oil, PEG 8 Stearate, PG Caprylate / Caprate, PG Dicaprylate / Caprate, PG Dipelargonate, PG Monostearate, Phytantriol, Polyglyceryl-3-Diisostearate, PPG 10 Cetyl Ether, PPG 2 Myristyl Propionate, PPGIt may also contain ceteth-10 phosphate, sorbitan isostearate, sorbitan oleate, squalene, steareth-10, stearateh-2, steareth-20, stearic acid, TEA stearate, stearyl alcohol, stearyl heptanoate, triethanolamine, water soluble sulfur, xylene, or zinc dioxide.
[0021] The formulations of the present disclosure may include a cationic surfactant at a concentration of about 1 mM, about 20 mM, about 50 mM, about 75 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the formulations of the present disclosure may include a cationic surfactant (e.g., CTAC or CTAB) at a concentration of about 1 mM. In some embodiments, the formulations of the present disclosure may include a cationic surfactant (e.g., CTAC or CTAB) at a concentration of about 300 mM. In some embodiments, the formulations of the present disclosure may include a cationic surfactant (e.g., CTAC or CTAB) at a concentration of about 400 mM. In some embodiments, the formulations of the present disclosure may include a cationic surfactant (e.g., CTAC or CTAB) at a concentration of about 500 mM.
[0022] The formulations of the present disclosure can include a chelating agent at a concentration of about 1 mM, about 20 mM, about 50 mM, about 75 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the formulations of the present disclosure can include a chelating agent (e.g., DTPA or EDTA) at a concentration of about 10 mM. In some embodiments, the formulations of the present disclosure can include a chelating agent (e.g., DTPA or EDTA) at a concentration of about 250 mM. In some embodiments, the formulations of the present disclosure can include a chelating agent (e.g., DTPA or EDTA) at a concentration of about 300 mM. In some embodiments, the formulations of the present disclosure can include a chelating agent (e.g., DTPA or EDTA) at a concentration of about 400 mM. In some embodiments, the formulations of the present disclosure may include a chelating agent (eg, DTPA or EDTA) at a concentration of about 500 mM.
[0023] The formulations of the present disclosure can include a mixture of solvents, for example, a mixture of water and an organic solvent. The formulations of the present disclosure can include, for example, about 25%, about 50%, about 75%, or about 100% organic solvent. In some embodiments, the formulations of the present disclosure can include about 25% PG or DMSO and about 75% water. In some embodiments, the formulations of the present disclosure can include about 50% PG or DMSO and about 50% water. In some embodiments, the formulations of the present disclosure can include about 75% PG or DMSO and about 25% water. In some embodiments, the formulations of the present disclosure can be made of 100% organic solvent, for example, 100% PG or 100% DMSO.
[0024] The formulations of the present disclosure can further include dyes, pigments, or colorants. The formulations of the present disclosure can include organic dyes, pigments, or colorants; or inorganic dyes, pigments, or colorants. For example, the formulations of the present disclosure can be used with dyes such as Alcian Yellow GXS (Ingrain Yellow 1), Alizarin (Mordant Red 11), Alizarin Red S (Mordant Red 3), Alizarin Yellow GG (Mordant Yellow 1), Alizarin Yellow R (Mordant Orange 1), Azophloxine (Acid Red 1), Bismarck Brown R (Vesuvine Brown), Bismarck Brown Y (Vesuvine Phenylene Brown), Brilliant Cresyl Blue (Cresyl Blue BBS), Chrysoidine R (Basic Orange 1), Chrysoidine Y (Basic Orange 2), Congo Red (Direct Red 28), Crystal Violet (Basic Violet 3), Fuschsin Acid (Acid Violet 19), Gentian Violet (Basic Violet 1), Janus Green, Lissamine Fast Yellow (Acid Yellow 17), Malachite Green, Marthus Yellow (Acid Yellow 18), and the like. The dye may include, for example, Red Yellow 24), Meldola Blue (Phenylene Blue), Metanil Yellow (Acid Yellow 36), Methyl Orange (Acid Orange 52), Methyl Red (Acid Red 2), Naphthalene Black 12B (Amido Black 10B or Acid Black 1), Naphthol Green B (Acid Green 1), Naphthol Yellow S (Acid Yellow 1), Orange G (Acid Orange 10), Purpurin (Verantin), Rose Bengal (Acid Red 94), Sudan II (Solvent Orange 7), Titanium Yellow (Direct Yellow 9), Tropaeoline O (Sulfo Orange or Acid Orange 6), Tropaeoline OO (Acid Orange 5), Tropaeoline OOO (Acid Orange 7), Victoria Blue 4R (Basic Blue 8), Victoria Blue B (Basic Blue 26), Victoria Blue R (Basic Blue 11), or Xylene Cyanol FF (Acid Blue 147).
[0025] The formulations of the present disclosure can further include a viscosity adjusting agent, such as a thickening agent. For example, the formulations of the present disclosure can include a thickening agent, such as starch (e.g., arrowroot, corn starch, dogtooth violet starch, potato starch, sago, tapioca), vegetable gum (arginine, guar gum, locust bean gum, xanthan gum), protein (e.g., collagen, egg white, gelatin), sugar (e.g., agar, carrageenan), or sodium pyrophosphate.
[0026] The formulations of the present disclosure may further include a stabilizer. For example, the formulations of the present disclosure may include calcium-zinc, organic calcium, lead, and tin-based stabilizers. The formulations of the present disclosure may also include liquid and light stabilizers, such as hindered amine light stabilizers (HALS), benzophenone, or benzotriazole. Examples of stabilizers include tris(2,4-di-tert-butylphenyl)phosphite, antioxidants (e.g., oxygen scavengers, such as phosphites; persistent radical scavengers, such as butylated hydroxytoluene; antiozonants; sequestering agents; UV stabilizers). The formulations of the present disclosure may include gelling agents, such as alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, or gelatin. In some embodiments, thickeners, such as polyethylene glycol, synthetic carbomers, petrolatum, paraffin, and waxes, may be used in the formulations of the present disclosure.
[0027] The formulations of the present disclosure may further include a local anesthetic, such as lignocaine (lidocaine, Remicaine®, Petercaine®), bupivacaine (e.g., Macaine®), ropivacaine (e.g., Naropin®), prilocaine, amethocaine (e.g., tetracaine®), procaine, cinchocaine (e.g., dibucaine®), mepivacaine (e.g., Carbocaine®), or etidocaine. The formulations of the present disclosure may further comprise a tissue permeabilization agent. The formulations of the present disclosure may further comprise a tissue permeabilization agent, such as an organic solvent (e.g., methanol, acetone) or a detergent (e.g., saponin, Triton TM The composition may include a tissue permeabilization agent such as X-100, Tween®-20.
[0028] The formulations of the present disclosure may further comprise an emollient. The formulations of the present disclosure may further comprise lentil fruit extract, hexyl laurate, hexyldecanol, hydrogenated polyisobutene, hydrolyzed glycosaminoglycans, hydrolyzed jojoba esters, isoamyl laurate, Limnanthes alba, lyceum barbarum fruit extract, methyl gluceth-20, methyl glucose sesquistearate, methyl glucoside phosphate, millet seed extract, neopentyl glycol diheptanoate, octyldodecyl myristate, octyldodecyl neopentanoate, oleyl erucate, rice wax, polyglyceryl-10 laurate, tridecyl trimellitate, trimethylsiloxysilicate, trioctyldodecyl citrate, triticum volgare (wheat) germ extract, triticum vulgare oil, whey protein, ximenynic acid, cocos nucifera (coconut) fruit extract, caprylyl caprate / caprylyl caprate, ethylhexyl olive oil, urea, or tocopheryl acetate.
[0029] The formulations of the present disclosure can further include an exfoliant, such as betaine salicylic acid, beta hydroxy acid, bromelain, alpha hydroxy acid, ammonium glycolate, amygdalic acid, ananas sativus fruit extract, azelaic acid, gluconolactone, lactic acid, lactobionic acid, glycolic acid, malic acid, mandelic acid, papain, papaya extract, polyhydroxy acid, salicylic acid, tartaric acid, or urea. The formulations of the present disclosure can further include amino acids, peptides, proteins, or proteases. In some embodiments, the formulations of the present disclosure can include poly-L-lysine, arginine, bacitracin, milk hydrolysate, alcalase, collagenase, or keratinase.
[0030] The formulation of the present disclosure may further include an antibiotic. The formulation of the present disclosure may further include an antibiotic, such as a penicillin, a cephalosporin, a macrolide, a fluoroquinolone, a sulfonamide, a tetracycline, or an aminoclycoside. For example, the formulation of the present disclosure may further include a penicillin, such as penicillin or amoxicillin. The formulation of the present disclosure may further include a cephalosporin, such as cephalexin. The formulation of the present disclosure may further include a macrolide, such as erythromycin, clarithromycin, or azithromycin. The formulation of the present disclosure may further include a fluoroquinolone, such as ciprofloxacin, levofloxacin, or ofloxacin. The formulation of the present disclosure may further include a sulfonamide, such as cotrimoxazole or trimethoprim. The formulation of the present disclosure may further include a tetracycline, such as tetracycline (sumycin, panmycin) or doxycycline. The formulation of the present disclosure may further include an aminoglycoside, such as gentamicin or tobramycin.
[0031] In some embodiments, the formulations of the present disclosure can include a cationic surfactant, a chelating agent, an organic solvent, and an antibiotic, such as polymyxin B. In some embodiments, the formulations of the present disclosure can include 1) CTAC or CTAB; 2) DTPA or EDTA; 3) PG or DMSO; and 4) an antibiotic, such as polymyxin B. The active compounds can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancers, buffers, and preservatives.
[0032] The compounds can also be formulated as rectal compositions, such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, gelatinous suppositories, or retention enemas, containing conventional suppository bases, such as cocoa butter or other glycerides, and synthetic polymers, such as polyvinylpyrrolidone and PEG. In compositions in suppository form, low melting waxes, such as mixtures of fatty acid glycerides, which may be combined with cocoa butter, can be melted. In carrying out the method of treatment or use provided by the present invention, a therapeutically effective amount of the compound described herein is administered as a pharmaceutical composition to a subject having a disease or condition to be treated.In some embodiments, the subject is a mammal, such as a human.The therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used, and other factors.The compound can be used alone or in combination with one or more therapeutic agents as components of a mixture.
[0033] The pharmaceutical composition can be formulated with one or more physiologically acceptable carriers, including excipients and auxiliaries that facilitate the processing of active compounds into pharmaceutical preparations.The formulation can be modified depending on the route of administration selected.The pharmaceutical composition containing the compound described herein can be prepared, for example, by mixing, dissolving, emulsifying, encapsulating, encapsulating or compressing processes. The pharmaceutical composition may include at least one pharma- ceutically acceptable carrier, diluent, or excipient and a compound described herein in free base or pharma- ceutically acceptable salt form. The pharmaceutical composition may contain solubilizers, stabilizers, tonicity enhancers, buffers, and preservatives.
[0034] The method of making compositions containing the compounds described herein includes formulating the compounds with one or more inert, pharma- ceutically acceptable excipients or carriers to form solid, semi-solid, or liquid compositions. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets. Liquid compositions include, for example, solutions in which the compounds are dissolved, emulsions containing the compounds, or solutions containing liposomes, micelles, or nanoparticles containing the compounds disclosed herein. Semi-solid compositions include, for example, gels, suspensions, and creams. The compositions may be in a liquid solution or suspension, a solid form suitable for solution or suspension in liquid before use, or may exist as an emulsion. These compositions may also contain small amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharma- ceutical acceptable additives. Non-limiting examples of dosage forms suitable for use in the present invention include liquids, powders, gels, nanosuspensions, nanoparticles, microgels, aqueous or oily suspensions, emulsions, and any combination thereof. Non-limiting examples of pharma- ceutically acceptable excipients suitable for use in the present invention include binders, disintegrants, anti-adherents, antistatic agents, surfactants, antioxidants, coating agents, colorants, plasticizers, preservatives, suspending agents, emulsifying agents, antimicrobial agents, spheronization agents, and any combination thereof.
[0035] The composition of the present invention may be, for example, an immediate release form or a controlled release formulation. An immediate release formulation may be formulated so that the compound can act quickly. Non-limiting examples of immediate release formulations include formulations that are easily soluble. A controlled release formulation may be a pharmaceutical formulation in which the release rate and release profile of the active agent are adapted to match physiological and chronotherapeutic requirements, or the active agent is formulated to release at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., synthetic or natural), other gelling agents (e.g., gel-forming dietary fibers), matrix-based formulations (e.g., formulations that include polymeric materials in which at least one active ingredient is dispersed), granules in a matrix, polymeric mixtures, and granular masses.
[0036] In some embodiments, the controlled release formulation is a delayed release form.Delayed release form can be formulated to delay the action of compound for a long time.Delayed release form can be formulated to delay the release of effective dose of one or more compounds for, for example, about 4, about 8, about 12, about 16, or about 24 hours. The controlled release formulation may be a sustained release form.The sustained release form can be formulated, for example, to sustain the action of the compound for a long period of time.The sustained release form can be formulated to provide an effective dose of any compound described herein (for example, provide a physiologically effective blood profile) for about 4, about 8, about 12, about 16 or about 24 hours.
[0037] Non-limiting examples of pharma- ceutically acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety. Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, the compound of the present invention is administered in combination with, before or after antibiotics. If simultaneously, multiple therapeutic agents can be provided in a single integrated form or in multiple forms, for example, as multiple separate topical treatments. The agents can be packaged together or separately in a single package or multiple packages. One or all therapeutic agents can be given in multiple doses. If not simultaneously, the timing between multiple doses can vary by as much as about one month.
[0038] The therapeutic agents described herein can be administered before, during, or after the onset of a disease or condition, and the timing of administering the composition containing the therapeutic agent can vary. For example, the composition can be used as a prophylactic and can be administered continuously to a subject prone to a condition or disease to reduce the likelihood of the onset of the disease or condition. The composition can be administered to the subject as soon as possible after the onset of symptoms or onset. Administration of the therapeutic agent can begin within the first 48 hours of the onset of symptoms, within the first 24 hours of the onset of symptoms, within the first 6 hours of the onset of symptoms, or within 3 hours of the onset of symptoms. The initial administration can be by any practical route, such as any route described herein using any formulation described herein. The therapeutic agent can be administered as soon as practicable after the onset of a disease or condition is detected or suspected, for the length of time required to treat the disease, such as from about 1 month to about 3 months. The length of treatment can vary for each subject.
[0039] The pharmaceutical compositions described herein may be in unit dosage form suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. The unit dosage may be in the form of a package containing a discrete amount of the formulation. Non-limiting examples are topicals, vials, or ampoules packaged in packages. Aqueous suspension compositions may be packaged in single-dose non-reclosable containers. Multi-dose reclosable containers may be used, for example, with or without preservatives. The formulation for administration may be in unit dosage form, for example, ampoules, or may be in multi-dose containers with preservatives. The pharmaceutical compositions provided herein can be administered in conjunction with other treatments, such as chemotherapy, radiation, surgery, anti-inflammatory drugs, and selected vitamins. The other agents can be administered before, after, or concomitantly with the pharmaceutical composition.
[0040] Depending on the intended mode of administration, the pharmaceutical composition may be in the form of a solid, semi-solid or liquid dosage form such as, for example, a tablet, suppository, pill, capsule, powder, liquid, suspension, lotion, cream, or gel, e.g., in a unit dosage form suitable for single administration of a precise dosage amount. For solid compositions, non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate. Non-limiting examples of pharma- ceutically active agents suitable for combination with the compositions of the present disclosure include anti-infectives, i.e., aminoglycosides, antivirals, antibacterials, anticholinergics / antispasmotics, antidiabetics, antihypertensives, antineoplastics, cardiovascular agents, central nervous system agents, coagulation modifiers, hormones, immune agents, immunosuppressants, and eye drops.
[0041] Compounds can be delivered by liposome technology. The use of liposomes as drug carriers can increase the therapeutic index of compounds. Liposomes are composed of natural phospholipids and can contain mixed lipid chains with surface active properties (e.g., egg phosphatidylethanolamine). Liposome designs can use surface ligands to attach to unhealthy tissues. Non-limiting examples of liposomes include multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), and large unilamellar vesicles (LUVs). The physicochemical properties of liposomes can be tailored to optimize penetration through biological barriers and retention at the site of administration, reducing the likelihood of premature degradation and toxicity to non-target tissues. Optimal liposome properties depend on the route of administration, with larger liposomes showing better retention upon local injection and smaller liposomes being better suited to achieve passive targeting. PEGylation reduces liposome uptake by the liver and spleen, increases circulation time, and results in increased localization at inflamed sites due to the enhanced permeability and retention (EPR) effect. Furthermore, the surface of liposomes can be modified to achieve selective delivery of encapsulated drugs to specific target cells. Non-limiting examples of targeting ligands include monoclonal antibodies, vitamins, peptides, and polysaccharides specific for receptors enriched on the surface of disease-associated cells.
[0042] Non-limiting examples of dosage forms suitable for use in the present disclosure include liquids, elixirs, nanosuspensions, aqueous or oily suspensions, drops, syrups, and any combination thereof.Non-limiting examples of pharma- ceutically acceptable excipients suitable for use in the present disclosure include granulating agents, binders, lubricants, disintegrants, sweeteners, glidants, anti-adherents, antistatic agents, surfactants, antioxidants, gums, coating agents, colorants, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifiers, plant cellulosic materials, and spheronizing agents, and any combination thereof.
[0043] The compositions of the invention can be packaged as a kit. In some embodiments, the kit includes instructions for administration / use of the composition. The information can be, for example, a label. The information can recommend conditions and methods of administration. The instructions provide the subject and the supervising physician with the best direction to achieve optimal clinical results from the administration of the treatment. The information can be a label. In some embodiments, the label can be approved by a regulatory agency, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agency.
[0044] In some embodiments, the pharmaceutical compositions of the present disclosure can be formulated as a leave-on spray used to treat mold. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated as shampoos and soaps to treat ringworm in humans or animals. In some embodiments, the pharmaceutical compositions of the present disclosure are formulated as detergents to pre-treat or treat clothing items with fungal cells or spores.
[0045] The formulations of the present disclosure can be combined with other formulations to impart antibacterial properties to the other formulations. Non-limiting examples of formulations that can be combined with the formulations disclosed herein include Mouth Kote Dry Mouth Spray, Feminease® Feminine Moisturizer, and Pretz Nasal Spray.
[0046] Purity of the Compounds of the Invention Any of the compounds herein can be purified. The compounds herein can be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure. , at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure , at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure , at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure,It may be at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.
[0047] dosage The pharmaceutical compositions described herein may be in unit dosage form suitable for single administration of precise dosage. In unit dosage form, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. The unit dosage may be in the form of a package containing a discrete amount of the formulation. Non-limiting examples are liquids in vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multi-dose reclosable containers can be used, for example, in combination with a preservative. Preparations for parenteral injection can be in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.
[0048] The compounds described herein may be present in the composition in an amount of from about 1 mg to about 2000 mg; from about 100 mg to about 2000 mg; from about 10 mg to about 2000 mg; from about 5 mg to about 1000 mg, from about 10 mg to about 500 mg, from about 50 mg to about 250 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about It may be present in the range of 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, about 450 mg to about 500 mg, about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg, about 800 mg to about 850 mg, about 850 mg to about 900 mg, about 900 mg to about 950 mg, or about 950 mg to about 1000 mg.
[0049] The compounds described herein may be administered in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 10 ... g, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, or about 2000 mg.
[0050] subject The subject may be, for example, an elderly person, an adult, an adolescent, a child between 9 and 12 years old, a child, an infant between 2 and 4 years old, an infant, and a non-human animal. In some embodiments, the subject is a patient. The non-human animal subject may be, for example, an animal (e.g., a mouse, a rat, a chicken, a rabbit, a dog, a cat, a frog, or a cow). The compounds of the present invention can be used on surfaces where the spread of drug-resistant bacteria is most likely to occur, such as hospitals, nursing homes, dormitories, homeless shelters, military barracks, schools, locker rooms, gyms, prisons, poultry farms, cattle pens, or pig pens. The method of the present invention can be applied to, for example, fomites, surgical instruments, tables, chairs, doors, tableware, bedding, beds, and keyboards. In some embodiments, the method of the present invention can be applied to plants infected with, for example, fungi, bacteria, parasites, or viruses.The administration can be, for example, to kill or suppress plant fungi, bacteria, parasites, or viruses, or to kill or suppress pathogens that harm or present a risk of harming plants or fungi, or to reduce the possibility of such risk.For example, it can be applied to agriculture to suppress the spread and damage caused by agriculturally harmful microorganisms.
[0051] formulation Non-limiting examples of formulations of the present disclosure are shown in Table 1 below. [Table 1]
[0052] In some embodiments, the formulation in Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, and propylene glycol. In some embodiments, the formulation in Table 1 comprises CTAB, DTPA or a pharma- ceutically acceptable salt thereof, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAC, about 10 mM DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAB, about 10 mM Ca-DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAB, about 10 mM DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAC, about 10 mM Ca-DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 2 mM CTAC, about 20 mM DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 2 mM CTAB, about 20 mM DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 2 mM CTAB, about 20 mM Ca-DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises about 2 mM CTAC, about 20 mM Ca-DTPA, and propylene glycol. In some embodiments, the formulation in Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, propylene glycol, and polymyxin B. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAC, about 10 mM DTPA, propylene glycol, and about 25 μg / mL polymyxin B. In some embodiments, the formulation in Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, propylene glycol, and water. In some embodiments, the formulation in Table 1 comprises about 400 mM CTAC, about 500 mM DTPA, and a solvent mixture consisting of about 25% propylene glycol and about 75% water. In some embodiments, the formulation of Table 1 comprises about 500 mM CTAC, about 300 mM DTPA, and a solvent mixture consisting of about 25% propylene glycol and about 75% water.In some embodiments, the formulation of Table 1 comprises about 400 mM CTAC, about 250 mM DTPA, and a solvent mixture consisting of about 25% propylene glycol and about 75% water. In some embodiments, the formulation of Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, DMSO, and water. In some embodiments, the formulation of Table 1 comprises about 400 mM CTAC, about 500 mM DTPA, and a solvent mixture consisting of about 25% DMSO and about 75% water. In some embodiments, the formulation of Table 1 comprises about 500 mM CTAC, about 300 mM DTPA, and a solvent mixture consisting of about 25% DMSO and about 75% water. In some embodiments, the formulation of Table 1 comprises about 400 mM CTAC, about 250 mM DTPA, and a solvent mixture consisting of about 25% DMSO and about 75% water. In some embodiments, the formulation of the present disclosure comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, ethanol, and water. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAC, about 10 mM DTPA, and a solvent mixture consisting of about 50% ethanol and about 50% water. In some embodiments, the formulation in Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, glycerol, and water. In some embodiments, the formulation in Table 1 comprises about 1 mM CTAC, about 10 mM DTPA, and a solvent mixture consisting of about 25% glycerol and about 75% water. In some embodiments, the formulation in Table 1 comprises CTAC, DTPA or a pharma- ceutically acceptable salt thereof, and water. In some embodiments, the formulation in Table 1 comprises about 10 mM CTAC, about 100 mM DTPA, and water. In some embodiments, the formulation in Table 1 comprises CTAB, DTPA and a pharma- ceutically acceptable salt thereof, and water. In some embodiments, the formulation in Table 1 comprises about 10 mM CTAC, about 100 mM DTPA, and water.
[0053] A pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form can be used to kill a microorganism. In some embodiments, a method of killing a microorganism comprises administering to the microorganism a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form. Non-limiting examples of microorganisms that can be killed by application of a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form include bacteria, gram positive bacteria, gram negative bacteria, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Burkholderia cepacia, Streptococcus pyogenes, Stenotrophomonas maltophilia, Bacillus subtilis, Mycobacterium abscessus, Staphylococcus aureus, Staphylococcus pyogenes ... aureus, Staphylococcus epidermidis, Propionibacterium acnes, Streptococcus mutans, Bacillus anthracis, Francisella tularensis, Yersinia pestis, Clostridium botulinum, Coxiella burnetii, Brucella species, Burkholderia mallei, Clostridium perfringens, Vibrio cholerae, Porphyromonas gingivalis, Proteus mirabilis, Salmonella enteriditis, Shigella flexneri, Xanthomonas campestris, Clavibacter species sp), fungi, Candida auris, Trichophyton rubrum, Aspergillus niger, Candida krusei, Geomyces destructans, Trichophyton rubrum, molds, yeasts, Candida albicans, Candida parapsilosis, Candida glabrata, Candida haemulonii, Candida duobuschaemulonii, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gattii, chytrid fungus, viruses, Lassa fever virus, Junin virus, Machupo virus, Ebola virus, Marburg virus, soy acne, Nipah virus, Hantavirus, Nairo virus, Varicella zoster virus, paramyxovirus, measles virus, rhinovirus, coronavirus, respiratory syncytial virus, influenza virus, norovirus, hepatitis A, rotavirus, astrovirus, and Norwalk-like virus.
[0054] A pharmaceutical composition comprising the formulation of Table 1 in a unit dosage form can be used to treat an infectious disease in a subject. In some embodiments, a method of treating an infectious disease in a subject comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the formulation of Table 1. An infectious disease treated with a pharmaceutical composition comprising the formulation of Table 1 in a unit dosage form can be caused by, for example, a microorganism. Non-limiting examples of microorganisms that can cause an infectious disease that can be treated by administering to a subject a formulation of Table 1 include bacteria, gram-positive bacteria, gram-negative bacteria, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Burkholderia cepacia, Streptococcus pyogenes, Stenotrophomonas maltophilia, Bacillus subtilis, Mycobacterium abscessus, Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes, Streptococcus mutans, Bacillus anthracis, Francisella tularensis, Yersinia pestis, Clostridium botulinum, Coxiella burnetii, Brucella species, Burkholderia mallei, Clostridium perfringens, Vibrio cholerae, Porphyromonas gingivalis, Proteus mirabilis, Salmonella enteriditis, Shigella flexneri, Xanthomonas campestris, Clavibacter species, fungi, Candida albicans ulis, Trichophyton rubrum, Aspergillus niger, Candida krusei, Geomyces destructans, Trichophyton rubrum, mold, yeast, Candida albicans, Candida parapsilosis, Candida glabrata, Candida haemulonii, Candida duobushaemulonii, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gattii, chytrid fungus, viruses, Lassa fever virus, Junin virus, Machupo virus, Ebola virus, Marburg virus, soy acne, Nipah virus, Hantavirus, Nairo virus, Varicella zoster virus, paramyxovirus, measles virus, rhinovirus, coronavirus, respiratory syncytial virus, influenza virus, norovirus, hepatitis A, rotavirus, astrovirus, and Norwalk-like virus.
[0055] A pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form can be used to disinfect a surface. In some embodiments, a method of disinfecting a surface comprises administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form to a surface in need thereof. Surfaces that can be disinfected by administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form can be infected with microorganisms. Non-limiting examples of microorganisms that can infect surfaces that can be disinfected by administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form include bacteria, gram-positive bacteria, gram-negative bacteria, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Burkholderia cepacia, Streptococcus pyogenes, Stenotrophomonas maltophilia, Bacillus subtilis, Mycobacterium abscessus, Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium erythroides, and the like. Umbilical cord blood, Streptococcus mutans, Bacillus anthracis, Francisella tularensis, Yersinia pestis, Clostridium botulinum, Coxiella burnetii, Brucella species, Burkholderia mallei, Clostridium perfringens, Vibrio cholerae, Porphyromonas gingivalis, Proteus mirabilis, Salmonella enteriditis, Shigella flexneri, Xanthomonas campestris, Clavibacter species, fungi, Candida auris, Trichophyton rubrum, Aspergillus niger, Candida krusei, Geomyces destructans, Trichophyton rubrum, mold, yeast, Candida albicans, Candida parapsilosis, Candida glabrata, Candida haemulonii, Candida duobuschaemulonii, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gattii, chytrid fungus, viruses, Lassa fever virus, Junin virus, Machupo virus, Ebola virus, Marburg virus, soy acne, Nipah virus, Hantavirus, Nairo virus, Varicella zoster virus, paramyxovirus, measles virus, rhinovirus, coronavirus, respiratory syncytial virus, influenza virus, norovirus, hepatitis A, rotavirus, astrovirus, and Norwalk-like virus.
[0056] A pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form can be used to sterilize produce. In some embodiments, a method of sterilizing produce comprises administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form to produce in need thereof. Produce that can be sterilized by administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form can be infected with microorganisms. Non-limiting examples of microorganisms that can infect produce that can be sterilized by administering a pharmaceutical composition comprising the formulation of Table 1 above in a unit dosage form include bacteria, gram-positive bacteria, gram-negative bacteria, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Burkholderia cepacia, Streptococcus pyogenes, Stenotrophomonas maltophilia, Bacillus subtilis, Mycobacterium abscessus, Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium erythrorhizae, and the like. Acne, Streptococcus mutans, Bacillus anthracis, Francisella tularensis, Yersinia pestis, Clostridium botulinum, Coxiella burnetii, Brucella species, Burkholderia mallei, Clostridium perfringens, Vibrio cholerae, Porphyromonas gingivalis, Proteus mirabilis, Salmonella enteriditis, Shigella flexneri, Xanthomonas campestris, Clavibacter species, fungi, Candida auris, Trichophyton rubrum, Aspergillus niger, Candida krusei, Geomyces destructans, Trichophyton rubrum, mold, yeast, Candida albicans, Candida parapsilosis, Candida glabrata, Candida haemulonii, Candida duobuschaemulonii, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gattii, chytrid fungus, viruses, Lassa fever virus, Junin virus, Machupo virus, Ebola virus, Marburg virus, soy acne, Nipah virus, Hantavirus, Nairo virus, Varicella zoster virus, paramyxovirus, measles virus, rhinovirus, coronavirus, respiratory syncytial virus, influenza virus, norovirus, hepatitis A, rotavirus, astrovirus, and Norwalk-like virus. EXAMPLES
[0057] Example 1 Composition of the formulation Formulations were prepared using various concentrations of cetyltrimethylammonium bromide (CTAB) or cetyltrimethylammonium chloride (CTAC) and diethylenetriaminepentaacetic acid (DTPA) dissolved in aqueous solutions of propylene glycol (PG) or dimethylsulfoxide (DMSO). Solutions were prepared to contain 25% by volume of PG or DMSO and 75% by volume of CTAC and DTPA. Table 1 shows the preparation of formulations MM1-MM19.
[0058] Example 2 Testing the efficacy of MM1 To test the efficacy of the MM1 solution, concentrated MM1 (500 mM DTPA + 400 mM CTAC) was diluted 1:10, 1:100, 1:1000, and 1:10000 in an aqueous solution of 25% PG. Five microliters of the diluted MM1 solution was spotted onto a lawn of multidrug-resistant C. auris (CDC 0385).
[0059] A 50 mL tube containing YM medium was inoculated with a culture of multidrug-resistant C. auris (CDC 0385) and incubated at 37°C for 24 h in a rotary shaking incubator. 100 μL of C. auris (approximately 1 × 10 8 CFU / mL were spread onto 100 mm x 15 mm square dishes containing Mueller-Hinton agar (MHA). When a lawn of C. auris was spread, 5 μL of 1:10, 1:100, 1:1000, and 1:10000 dilutions of concentrated MM1 were spotted onto each area of the inoculated MHA plate. The plates were then incubated at 37°C for 48 hours.
[0060] Figure 1 shows that concentrated MM1 was effective in killing multidrug-resistant C. auris (CDC 0385) at various dilution levels. 1 shows the effect of concentrated MM1 without dilution; 2 shows the effect of concentrated MM1 diluted 1:10 in 25% PG; 3 shows the effect of concentrated MM1 diluted 1:100 in 25% PG; 4 shows the effect of concentrated MM1 diluted 1:1000 in 25% PG; 5 shows the effect of concentrated MM1 diluted 1:10000 in 25% PG. The diameter of the clearance zone decreased with dilution. Within the death circle, the MM1 solution completely killed C. auris, which was observed along with a reduced impermeability within the fungal lawn. Increasing the volume of the diluted MM1 solution sterilized a larger surface area.
[0061] Example 3 Effect of antifungal preparations on fungi The formulation of Example 1 was tested against commercially available antifungal formulations. The active and inactive ingredients of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream are shown in Table 2.
[0062] [Table 2]
[0063] MM1, MM2, MM3, MM4, MM5, MM6, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Cream, Tinactin® Cream, and Lamisil® Cream were tested for their efficacy in killing Candida albicans, T. rubrum, Aspergillus niger, drug-resistant Candida parapsilosis (CDC 0339), drug-resistant Candida aurus (CDC 0383), multidrug-resistant Candida auris (CDC 0385), and Candida krusei (CDC 0397).
[0064] Candida albicans (ATCC 26555), drug-resistant Candida parapsilosis (CDC 0339), drug-resistant C. auris (CDC 0383), multidrug-resistant C. auris (CDC 0385), and Candida krusei (CDC 0397) were grown in YM medium for 24 hours at 37°C in a rotary shaking incubator. T. rubrum (ATCC 28188) was grown in YM medium for 21 days at 30°C, and A. niger was grown in YM medium for 5 days at 30°C. Approximately 1 × 10 8 100 μL of each culture at CFU / mL was spread onto a 100 mm x 15 mm square dish containing MHA. Once the lawn of each fungal strain was spread, 10 μL of MM1, MM2, MM3, MM4, MM5, and MM6 were spotted onto each area of the inoculated MHA plate. Approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were tested for killing efficacy against Candida albicans (ATCC 26555), T. rubrum (ATCC 28188), A. niger, drug-resistant C. parapsilosis (CDC 0339), drug-resistant C. auris (CDC 0383), multidrug-resistant C. auris (CDC 0385), and C. krusei (CDC 0397) after incubation at 37°C for 48 hours for Candida spp., 28°C for 30 days for T. rubrum, and 28°C for 7 days for A. niger.
[0065] a. Candida albicans (ATCC 26555) MM1, MM2, MM3, MM4, MM5, MM6, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were tested for their efficacy in killing Candida albicans. Table 3 shows the formulations used on MHA plates infected with Candida albicans.
[0066] [Table 3]
[0067] Panel A of FIG. 2 shows the diameter (cm) of the clearing of Candida albicans when treated with MM1 (1), Derman® Antifungal Cream (1A), MM2 (2), and Equate® Athlete's Foot Antifungal Cream (2A). The bold circle encloses the diameter (cm) of the clearing for Candida albicans treated with MM1. Panel B of FIG. 2 shows the diameter (cm) of the clearing of Candida albicans when treated with MM3 (3), Lotrimin® Ultra Athlete's Foot Cream (3A), MM4 (4), and Tinactin® Athlete's Foot Cream (4A). Panel C of FIG. 2 shows the diameter (cm) of the clearing of Candida albicans when treated with MM5 (5), Lamisil® Athlete's Foot Cream (5A), MM6 (6), and Polymyxin B (PMB).
[0068] FIG. 3 shows the comparative effectiveness of the formulations in killing Candida albicans. The data shows that MM1 was equally effective as Equate® Athlete's Foot Antifungal Cream in killing Candida albicans. Formulations MM1-MM6 were significantly more effective than Derman® Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream in killing Candida albicans. A clearing diameter of 0 cm indicates that the formulation did not kill Candida albicans and / or fungal regrowth was observed.
[0069] The residual protective capacity of MM1 was tested against C. albicans. Three wells (Figure 4A, left wells) of a 12-well MHA plate were flooded with 500 μL of 1:1000 MM1 for 1 min. The MM1 formulation was removed and the wells were washed with 500 μL of PBS to remove residual MM1. Three different wells (Figure 4A, right wells) of the MHA plate were flooded with 500 μL of PBS for 1 min. The wells were emptied, one well was flooded with 500 μL of PBS (positive control) and two wells were washed with 500 μL of 1:1000 MM1. The wells were dried and filled with undiluted C. albicans (1 × 10 8 The dry surface of the wells was streaked with a lawn of 1:1000 (CFU / mL) and incubated at 37 °C for 48 h. Figure 4A shows the residual protective ability of MM1 to kill C. albicans. Wells pre-treated with MM1 and washed with PBS showed more fungal growth than wells pre-treated with PBS and washed with 1:1000 MM1. This result suggests that the 1:1000 diluted MM1 formulation did not provide residual protection, but washing with MM1 and further diluting the concentration with PBS reduced the killing efficacy of MM1.
[0070] Lawn of Candida albicans (approximately 1 x 10 in 50 µL) 8 CFU / mL) were spread into six wells of an MHA plate and incubated at 37°C for 1 day. Wells were treated with 500 μL of PBS (Figure 4B, row 1), 500 μL of 1:1000 MM1 (Figure 4B, row 2), or 500 μL of MM1 (Figure 4B, row 3). After 2 min, the solution was removed and the plate was incubated at 37°C for 1 day. Figure 4B shows that treatment with MM1 and 1:1000 MM1 resulted in quenching of pre-existing C. albicans infection.
[0071] b. Trichophyton rubrum (ATCC 28188) MM1, MM2, MM3, MM4, MM5, MM6, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were tested for efficacy in killing Trichophyton rubrum. Table 4 shows the formulations used on MHA plates infected with Trichophyton rubum.
[0072] [Table 4]
[0073] Panel A of FIG. 5 shows the diameter (cm) of T. rubrum clearing when treated with MM1 (1), Derman® Antifungal Cream (1A), MM2 (2), and Equate® Athlete's Foot Antifungal Cream (2A). The bold circle encloses the diameter (cm) of the clearing for T. rubrum treated with MM1. Panel B of FIG. 5 shows the diameter (cm) of T. rubrum clearing when treated with MM3 (3), Lotrimin® Ultra Athlete's Foot Cream (3A), MM4 (4), or Tinactin® Athlete's Foot Cream (4A). Panel C of FIG. 5 shows the diameter (cm) of T. rubrum clearing when treated with MM5 (5), Lamisil® Athlete's Foot Cream (5A), MM6 (6), or Polymyxin B (PMB). The left panel of Panel D of Figure 5 shows a magnified image of the circle shown in Panel C of Figure 5. The magnified image shows that colonies have regrown in the area treated with Lamisil® Athlete's Foot Cream. The right panel of Panel D of Figure 5 shows a magnified image of the circle shown in Panel B of Figure 5. The magnified image shows that colonies have regrown in the area treated with Lotrimin® Ultra Athlete's Foot Cream.
[0074] FIG. 6 shows the comparative efficacy of the formulations in killing T. rubrum after 12 and 24 days of treatment. The data shows that MM1 and MM4 were equally effective as Lotrimin® Ultra Athlete's Foot Cream and Tinactin® Athlete's Foot Cream in killing T. rubrum after 12 and 24 days of treatment. Lamisil® Athlete's Foot Cream was the most effective in killing T. rubrum after 12 days of treatment. MM1-MM6 had the same clearing diameter after 12 and 24 days of treatment. Derman® and Equate® Athlete's Foot had a reduced clearing diameter after 12 days. Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream showed almost complete regrowth of the fungus after 24 days of treatment. A clearing diameter of 0 cm indicates that the formulation did not kill T. rubrum and / or there was fungal regrowth.
[0075] The ability of MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream to kill T. rubrum and prevent fungal regrowth was tested. T. rubrum was grown in YM medium for 21 days at 30° C. A lawn of undiluted T. rubrum was spread onto an MHA plate. 10 μL of MM1 was spotted onto the inoculated MHA plate, and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were applied to different parts of the MHA plate to test initial killing efficacy and ability to kill through penetration. The plates were incubated at 28° C. for 12 and 24 days.
[0076] Table 5 shows the formulations used on the MHA plates infected with T. rubrum. [Table 5]
[0077] Panel A of Figure 7 shows the diameter (cm) of T. rubrum clearing after 12 days of treatment with MM1, Derman® (1), Equate® Athlete's Foot (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of Figure 7 shows the diameter (cm) of T. rubrum clearing after 12 days of treatment with MM1, Tinactin® Athlete's Foot Cream (4), and Lamisil® Athlete's Foot Cream (5). Panel C of Figure 7 shows the diameter (cm) of T. rubrum clearing after 30 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot (2), and Lotrimin® Ultra Athlete's Foot Cream (3). Panel D of Figure 7 shows the diameter (cm) of T. rubrum clearing after 30 days treatment with MM1, Tinactin® athlete's foot cream, and Lamisil® athlete's foot cream. The box in Panel D of Figure 7 shows that colonies had regrown in the area treated with Lamisil®. No colony regrowth was observed for the area treated with MM1. Figure 8 shows a comparative efficacy of the formulations in killing T. rubrum. The data shows that MM1 was more effective than Derman® Antifungal Cream, Equate® Athlete's Foot, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream in killing T. rubrum after 12 days of application and after 30 days of application.
[0078] c. Aspergillus niger (teaching strain) The efficacy of the disclosed formulation and the commercial product was compared using wood samples infected with A. niger. Three pieces of wood were inoculated with A. niger spores previously grown on MHA plates using the tip of a sterile cotton swab. The wood samples were stored in an incubator at 28° C. for one month. One piece of wood was treated with MM1 and the second piece was left untreated and used as a control. Panels A of FIG. 9 through G of FIG. 9 show images of untreated wood samples infected with A. niger. Panels H of FIG. 9 through M of FIG. 9 show images of wood samples infected with A. niger and treated with MM1.
[0079] Two days after treatment with MM1, the MM1-treated and control wood samples were wiped under sterile conditions, placed on MHA plates, and incubated at 28° C. for 2 and 5 days. Panel A of FIG. 10 shows the MHA plate wiped with the MM1-treated wood sample after 2 days. Panel B of FIG. 10 shows the MHA plate wiped with the untreated wood sample after 2 days. Panel C of FIG. 10 shows the MHA plate wiped with the MM1-treated wood sample after 5 days. Panel D of FIG. 10 shows the MHA plate wiped with the untreated wood sample after 5 days. The fungal load of the wood samples treated once with MM1 was lower than that of the untreated wood samples. The data show that the wood samples treated with MM1 were able to suppress pre-existing mold on the wood samples with a single treatment with MM1.
[0080] The toxicity of MM1 was tested by infecting MHA plates with undiluted A. niger. 5 μL of MM1 and 5 μL of Lamisil® Athlete's Foot Cream (terbinafine) were spotted onto A. niger-infected MHA plates. The MHA plates were then incubated at 28° C. for 5 days. Panel A of FIG. 11 shows the front side of an A. niger-infected MHA plate treated with MM1 and Lamisil® Athlete's Foot Cream after 5 days of incubation. Panel B of FIG. 11 shows the back side of an A. niger-infected MHA plate treated with MM1 and Lamisil® Athlete's Foot Cream after 5 days of incubation. FIG. 12 shows a comparison of the spot spread diameter (cm) of A. niger-infected MHA plates treated with MM1 and Lamisil® Athlete's Foot Cream. The data show that treatment of A. niger infected MHA plates with MM1 resulted in a spreading diameter that was more than four times larger than the spreading diameter resulting from treatment of A. niger infected MHA plates with Lamisil® Athlete's Foot Cream.
[0081] The A. niger infected MHA plates were treated with MM1 and Lamisil® Athlete's Foot Cream (terbinafine) and incubated at 28° C. for an additional 27 days (total incubation time of 32 days). Panel A of FIG. 13 shows the front side of the A. niger infected MHA plate treated with MM1 and Lamisil® Athlete's Foot Cream after 32 days of incubation time. Panel B of FIG. 13 shows the back side of the A. niger infected MHA plate treated with MM1 and Lamisil® Athlete's Foot Cream after 32 days of incubation time. The results show that after 32 days of incubation, the spots treated with MM1 were more effective at killing A. niger than the Lamisil® Athlete's Foot Cream, as indicated by the larger diameter of spread (cm) resulting from the MM1 treatment.
[0082] To test the residual protective capacity of MM1, three wells of a 6-well plate were treated with 500 μL of MM1 and inoculated with A. niger, and another three wells of a 6-well plate were treated with 500 μL of MHB and inoculated with A. niger. Of the three wells initially treated with 500 μL of MM1 and inoculated with A. niger, one well was subsequently treated with MHB, and two wells were not further treated. Of the three wells initially treated with 500 μL of MHB and inoculated with A. niger, one well was subsequently treated with 500 μL of MHB, and two wells were subsequently treated with 500 μL of MM1. The 6-well plates were incubated for 2 days at 28°C. Wells pre-treated with MHB, inoculated with A. niger, and again treated with the MHB control were transferred onto MHA plates and incubated at 28°C for 2 and 7 days. Wells pre-treated with MHB, inoculated with A. niger, and treated with MM1 were transferred onto MHA plates and incubated for 2 and 7 days at 28° C. The 6-well plates were further incubated at 28° C. for an additional 5 days (total incubation time of 7 days). Wells pre-treated with 500 μL of MM1 and wells inoculated with A. niger and then treated with MM1 showed no A. niger growth.
[0083] Panel A of FIG. 14 shows a 6-well plate with three wells pre-treated with MM1 and three wells pre-treated with MHB control. The upper panel of Panel B of FIG. 14 shows an MHA plate treated with MHB, inoculated with A. niger, and wiped with wells treated with MHB. The lower panel of Panel B of FIG. 14 shows an MHA plate pre-treated with MHB, inoculated with A. niger, and wiped with wells treated with MM1. Panel C of FIG. 14 shows the 6-well plate after 7 days of incubation. The wells show that pre-treatment of wells with MM1 prior to inoculation with A. niger, and treatment with MM1 after inoculation with A. niger, were able to prevent A. niger regrowth for an extended period of time.
[0084] d. Drug-resistant Candida parapsilosis (CDC 0339) The ability of MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream to kill drug-resistant Candida parapsilosis was tested. Candida parapsilosis (CDC 0339) was grown in YM medium for 24 hours at 37°C. A lawn of undiluted Candida parapsilosis (~1 × 10 8 CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM1 and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were spotted onto the MHA plates to test the killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0085] Table 6 shows the formulations used on agar plates infected with drug-resistant Candida parapsilosis. [Table 6]
[0086] Panel A of FIG. 15 shows the degree of clearing of drug-resistant Candida parapsilosis after 1 day when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of FIG. 15 shows the degree of clearing of drug-resistant Candida parapsilosis after 1 day when treated with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C of FIG. 15 shows the degree of clearing of drug-resistant Candida parapsilosis after 15 days when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D of Figure 15 shows the extent of clearing of drug-resistant Candida parapsilosis after 15 days of treatment with MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5).
[0087] FIG. 16 compares the efficacy of MM1 and commercial formulations in killing drug-resistant Candida parapsilosis after 1 and 15 days of treatment. The data show that MM1 was more effective than Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream in killing drug-resistant Candida parapsilosis after 1 and 15 days of treatment. Derman® Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were not effective in killing drug-resistant Candida parapsilosis, with clearance diameters less than 0.25 cm.
[0088] e. Drug-resistant C. auris (CDC 0383) MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Cream, Tinactin® Cream, and Lamisil® Cream were tested for their ability to kill drug-resistant C. auris (CDC 0383). Drug-resistant Candida auris (CDC 0383) was grown in YM medium for 24 hours at 37°C. A lawn of undiluted C. auris (~1 × 10 8 CFU / mL) was spread onto MHA plates. 10 μL of MM1 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were spotted onto different areas of the MHA plates to test the efficacy of the formulations in killing C. auris after an incubation period of 48 hours at 37° C.
[0089] Table 7 shows the formulations used on agar plates infected with drug-resistant C. auris (CDC 0383). [Table 7]
[0090] Panel A of Figure 17 shows the diameter (cm) of a clearing of drug-resistant C. auris (CDC 0383) after 1 day of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of Figure 17 shows the diameter (cm) of a clearing of drug-resistant C. auris (CDC 0383) after 1 day of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C of Figure 17 shows the diameter (cm) of a clearing of drug-resistant C. auris (CDC 0383) after 15 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D of Figure 17 shows the diameter (cm) of clearings of drug-resistant C. auris (CDC 0383) after 15 days of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5).
[0091] FIG. 18 shows the comparative efficacy of MM1 and commercial formulations in killing drug-resistant C. auris (CDC 0383) after 1 and 15 days of treatment. The data shows that MM1 was more effective at killing drug-resistant C. auris (CDC 0383) than Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream after 1 and 15 days of treatment. Derman® Antifungal Cream and Equate® Athlete's Foot Cream produced clearance diameters roughly half that of MM1. Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were not effective at killing drug-resistant C. auris (CDC 0383), with clearance diameters less than 0.25 cm.
[0092] f. Drug-resistant C. auris (CDC 0383) The ability of MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Cream, Tinactin® Cream, and Lamisil® Cream to kill multidrug-resistant C. auris (CDC 0383) was tested. Multidrug-resistant Candida auris (CDC 0383) was grown in YM medium for 24 hours at 37°C. A lawn of undiluted C. auris (~1 × 10 8 CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM1 and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were spotted onto different areas of the plates to test the efficacy of the formulations against C. auris after 48 hours of incubation at 37° C.
[0093] Table 8 shows the formulations used on agar plates infected with multidrug-resistant C. auris (CDC 0383). [Table 8]
[0094] Panel A of Figure 19 shows the diameter (cm) of clearings of drug-resistant C. auris (CDC 0383) when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of Figure 19 shows the diameter (cm) of clearings of drug-resistant C. auris (CDC 0383) when treated with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5).
[0095] FIG. 20 shows the comparative efficacy of MM1 and commercial formulations in killing drug-resistant C. auris (CDC 0383). The data shows that MM1 was more effective than Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream in killing drug-resistant C. auris (CDC 0383). Treatment with Derman® Antifungal Cream resulted in a clearance diameter less than half that of MM1. Treatment with Equate® Athlete's Foot Cream resulted in a clearance diameter approximately 75% that of MM1. Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were not effective in killing drug-resistant C. auris (CDC 0383), with clearance diameters approximately zero.
[0096] g. Multidrug-resistant C. auris (CDC 0385) The ability of MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream to kill drug-resistant C. auris (CDC 0385) was tested. Multidrug-resistant Candida auris (CDC 0385) was grown in YM medium for 24 hours at 37°C. A lawn of undiluted C. auris (~1 × 10 8 CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM1 and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Antifungal Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were spotted onto different areas of the plates to test the efficacy of the formulations in killing multi-resistant C. auris after 48 hours of incubation at 37° C.
[0097] Table 9 shows the formulations used on agar plates infected with multidrug-resistant C. auris (CDC 0385). [Table 9]
[0098] Panel A of Figure 21 shows the diameter (cm) of a clearing of multi-resistant C. auris (CDC 0385) after 1 day of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of Figure 21 shows the diameter (cm) of a clearing of multi-resistant C. auris (CDC 0385) after 1 day of treatment with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C of Figure 21 shows the diameter (cm) of a clearing of multi-resistant C. auris (CDC 0385) after 15 days of treatment with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D of Figure 21 shows the diameter (cm) of clearings of multidrug-resistant C. auris (CDC 0385) after 15 days of treatment with MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5).
[0099] Figure 22 shows the comparative efficacy of MM1 and a commercial formulation in killing multi-resistant C. auris (CDC 0385) after 1 or 15 days of treatment. The data shows that MM1 was more effective than Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, or Lamisil® Athlete's Foot Cream in killing multi-resistant C. auris (CDC 0385) after 1 or 15 days of treatment. Derman® Antifungal Cream resulted in approximately half the clearance diameter of MM1. Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were ineffective at killing multidrug-resistant C. auris (CDC 0385), with clearance diameters less than 0.25 cm.
[0100] The ability of MM1 and Monistat® 3 Complete Line to kill multidrug-resistant C. auris (CDC 0385) was compared. The active ingredient in Monistat® 3 Complete Line is miconazole nitrate (2%); the inactive ingredients in Monistat® 3 Complete Line are benzoic acid, cetyl alcohol, isopropyl myristate, polysorbate 60, potassium hydroxide, propylene glycol, purified water, and stearyl alcohol. Equal volumes of MM1 prepared in PBS (MM1(PBS)), MM1 prepared in PG (MM1(PG)), and Monistat® 3 Complete Line were applied to a lawn of multidrug-resistant C. auris (CDC 0385). Multidrug-resistant Candida auris (CDC 0385) was grown on MHA plates in YM medium for 24 hours at 37°C. A lawn of undiluted C. auris (~1 × 10 8CFU / mL) were spread onto MHA plates. 10 μL of MM1 was spotted onto the inoculated MHA plates, and approximately 10 μL drops of Monistat® 3 complete line were spotted onto different areas of the MHA plates to test their efficacy in killing multidrug-resistant C. auris after 48 hours of incubation at 37°C.
[0101] Figure 23 shows the comparative efficacy of Monistat® 3 complete line, MM1 prepared in PBS, and MM1 prepared in PG to kill multi-resistant C. auris (CDC 0385). The data shows that Monistat® 3 complete line was ineffective in killing multi-resistant C. auris (CDC 0385), with a clearance diameter of 0 cm. MM1 (PBS) and MM1 (PG) produced large diameter clearances, demonstrating efficacy in killing multi-resistant C. auris (CDC 0385).
[0102] The ability of MM1 to kill multidrug-resistant C. auris (CDC 0385) in the form of a mouthwash and douche was tested. 12-well plates filled with MHA were inoculated with multidrug-resistant C. auris (CDC 0385) and incubated overnight at 37° C., allowing multidrug-resistant C. auris (CDC 0385) to grow into a thick lawn of cells. 500 μL of 1× PBS was added to the control wells ( FIG. 24 , row A) and 500 μL of MM1 was added to the MM1 wells ( FIG. 24 , rows B and C). PBS and MM1 solutions were removed at 0 minutes (30 seconds), 5 minutes, 15 minutes, and 30 minutes after the initial addition of the solutions to simulate the time and coverage achieved with a typical mouthwash or douche. The plates were incubated at 37° C. for 4 days after treatment. FIG. 24 shows the 12-well plate used to simulate the use of MM1 as a mouthwash and douche. A single exposure to MM1 (30 s rinse) quenched and limited the growth of multidrug-resistant C. auris (CDC 0385) on heavily infected biofilms / surfaces. The ability of MM1 to kill multidrug-resistant C. auris (CDC 0385) on moist coelom-like pretreated surfaces was tested. Four wells of a 12-well plate coated with MHA were pretreated with 500 μL of MM1 or 500 μL of MHB (positive growth control) for 30 s, 5 min, 15 min, or 30 min. Except for MM1, the wells were washed three times with PBS. The wells were washed with PBS and inoculated with multidrug-resistant C. auris (CDC 0385). The plates were then incubated at 37° C. for 4 days.
[0103] Figure 25 shows the results for 1) wells pre-treated with MM1 and inoculated with multidrug resistant C. auris (CDC 0385), 2) wells pre-treated with MHB and inoculated with multidrug resistant C. auris (CDC 0385), 3) wells inoculated with multidrug resistant C. auris (CDC 0385) and treated with MM1, and 4) wells inoculated with multidrug resistant C. auris (CDC 0385) and treated with MHB. Wells pre-treated with MM1 and inoculated with multidrug resistant C. auris (CDC 0385) showed minimal growth of multidrug resistant C. auris (CDC 0385), while wells pre-treated with the MHB control and inoculated with multidrug resistant C. auris (CDC 0385) showed growth of multidrug resistant C. auris (CDC 0385). Wells initially inoculated with multidrug-resistant C. auris (CDC 0385) killed the fungus upon treatment with MM1, but showed greatest fungal growth when treated with the MHB control. Row C has no wells.
[0104] Figure 26 shows the comparative effect of MM1 and MHB control on the growth of multidrug-resistant C. auris (CDC 0385) when applied to the surface prior to inoculation with multidrug-resistant C. auris (CDC 0385) (black) or when applied to the surface after the surface was inoculated with multidrug-resistant C. auris (CDC 0385). The data shows that MM1 was effective in preventing the growth of and / or killing multidrug-resistant C. auris (CDC 0385). The y-axis is optical density at 595 nm, which corresponds to cell viability.
[0105] h. Candida krusei (CDC 0397) MM1, Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were tested for their ability to kill Candida krusei (CDC 0397). Candida krusei (CDC 0397) was grown in YM medium for 24 hours at 37°C. A lawn of undiluted Candida krusei (~100 μL of 1 × 10 8 CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM1 and approximately 10 μL drops of Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, or Lamisil® Athlete's Foot Cream were spotted onto different areas of the plates to test for killing efficacy after 48 hours of incubation at 37° C.
[0106] Table 10 shows the formulations used for infecting agar plates with Candida krusei (CDC 0397). [Table 10]
[0107] Panel A of FIG. 27 shows the clearing of Candida krusei (CDC 0397) after 1 day when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel B of FIG. 27 shows the clearing of Candida krusei (CDC 0397) after 1 day when treated with MM1, Tinactin® Athlete's Foot Cream (4), or Lamisil® Athlete's Foot Cream (5). Panel C of FIG. 27 shows the clearing of Candida krusei (CDC 0397) after 15 days when treated with MM1, Derman® Antifungal Cream (1), Equate® Athlete's Foot Cream (2), or Lotrimin® Ultra Athlete's Foot Cream (3). Panel D of Figure 27 shows clearing of Candida krusei (CDC 0397) after 15 days of treatment with a single dose of MM1, Tinactin® athlete's foot cream (4), or Lamisil® athlete's foot cream (5).
[0108] FIG. 28 shows the comparative efficacy of MM1 and commercial formulations in killing Candida krusei (CDC 0397). The data shows that MM1 was more effective at killing Candida krusei (CDC 0397) than Derman® Antifungal Cream, Equate® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream. Treatment with Derman® Antifungal Cream or Equate® Athlete's Foot Cream resulted in a clearance diameter that was approximately 30% of the clearance diameter of MM1. Both Derman® Antifungal Cream and Equate® Athlete's Foot Cream showed reduced clearance diameter after 15 days of treatment compared to the clearance diameter after 1 day of treatment. Treatment with Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream were ineffective at killing Candida krusei (CDC 0397), each resulting in a clearance diameter of less than 0.25 cm.
[0109] i. Unidentified plant fungi Unidentified plant fungi were treated with MM1 to test the efficacy of MM1 in killing unidentified plant fungi. 12-well MHA plates were inoculated with unidentified fungi swabbed from plants and incubated at 37° C. for one day to establish a thick layer of vegetative fungi. 500 μL of 1× PBS was added to control wells ( FIG. 29 , row A) and 500 μL of MM1 was added to MM1 wells ( FIG. 29 , rows B and C). PBS and MM1 solutions were removed 30 seconds, 1 minute, 2 minutes, and 3 minutes after the initial addition of the solutions. Plates were incubated at 30° C. for two days after treatment to determine the killing efficiency of MM1. Figure 29 shows a 12-well plate used to treat an unidentified plant fungus with MM1. Exposure of the plant fungus to MM1 for 30 seconds killed the plant fungus and limited its growth. Wells treated with PBS were infested with the plant fungus.
[0110] The residual protective capacity of MM1 against an unidentified plant fungus was tested. Three wells on the left side of a 6-well plate were first washed with MHB for 5 min and then treated with 500 μL of MM1 for an additional 5 min. All wells except MM1 were inoculated with an unidentified plant fungus. Three wells on the right side of a 6-well plate were first treated with 500 μL of MM1 for 5 min. After the 5 min treatment, MM1 was removed and wells were washed with MHB for an additional 5 min. MHB was removed and wells were inoculated with an unidentified plant fungus. On the left half of a 6-well plate, two of the three wells were pre-treated with 500 μL of MM1 and one well was treated with MHB to serve as a positive growth control. All three wells were inoculated with an unidentified plant fungus. In the right half of the 6-well plate, two of the three wells were pretreated with 500 μL of MM1 and then washed with 500 μL of MHB to determine MM1 residual protection upon further dilution. The remaining well was treated with 500 μL of MHB to serve as a positive growth control. All three wells were inoculated with an unidentified plant fungus.
[0111] Panel A of Figure 30 shows a 6-well plate in which two wells were pre-treated with MM1 without subsequent washing, two wells were pre-treated with MM1 and washed with MHB to remove residual MM1, and two wells were washed with MHB only to serve as positive growth controls after 2 days of incubation. Panel B of Figure 30 shows the unidentified plant fungus used in the residual protection assay. Panel C of Figure 30 shows a 6-well plate in which four wells were pre-treated with MM1 and two wells were pre-treated with MHB control after 7 days of incubation. The results show that pre-treatment of wells with MM1 prior to inoculation with the unidentified plant fungus inhibited plant fungal growth for extended periods of time.
[0112] Example 4 Bactericidal properties of MM7 against MRSA (BAA-44), Acinetobacter baumannii (ATCC 1797), Pseudomonas aeruginosa (ATCC 2114), and multidrug-resistant C. auris (CDC 0385) MRSA (BAA-44), Acinetobacter baumannii (ATCC 1797), Pseudomonas aeruginosa (ATCC 2114), and multidrug-resistant C. auris (CDC 0385) cells were grown overnight in MHB, diluted 1:10, and plated onto four different MHA plates. Each plate was spotted with 10 μL of MM7 and 10 μL of chlorhexidine gluconate 0.12% mouthwash. Plates were incubated overnight at 37°C. MM7 killed MRSA (BAA-44), Acinetobacter baumannii (ATCC 1797), Pseudomonas aeruginosa (ATCC 2114), and multidrug-resistant C. auris (CDC 0385) cells. MM7 showed similar activity to chlorhexidine gluconate 0.12% mouthwash in killing MRSA (BAA-44) and Pseudomonas aeruginosa (ATCC 2114). MM7 showed greater efficacy than chlorhexidine gluconate 0.12% mouthwash in killing Acinetobacter baumannii (ATCC 1797) and multidrug-resistant C. auris (CDC 0385).
[0113] Panel A of Figure 31 shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill MRSA (BAA-44). Panel B of Figure 31 shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill Acinetobacter baumannii (ATCC 1797). Panel C of Figure 31 shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill Pseudomonas aeruginosa (ATCC 2114). Panel D of Figure 31 shows the ability of MM7 and chlorhexidine gluconate 0.12% mouthwash to kill multidrug-resistant C. auris (CDC 0385).
[0114] Example 5 Preparation of MM8 A solution of DTPA was prepared by dissolving DTPA powder in a mixture of 50% sterile water and 50% 10 M NaOH to obtain a 500 mM stock solution. The pH of the DTPA stock solution was adjusted to pH ~7.4 using concentrated hydrochloric acid. A portion of the solution from the 780 mM CTAC stock solution was taken and placed in a sterile 1.6 mL microtube. A solution of PMB was prepared by dissolving 10 mg of polymyxin B (PMB) in 1 mL of sterile water and filtering the resulting solution through a 0.22 μm filter. MM8 was obtained by mixing 20 μL of the 500 mM DPTA stock solution, 1.2 μL of the 780 mM CTAC stock solution, 2.5 μL of the 10 mg / mL PMB solution, and 976 μL of PG. The final concentrations of the components of MM8 are shown in Table 11. [Table 11]
[0115] Example 6 Antifungal efficacy of MM8 The efficacy of MM8 as an antifungal and antibacterial agent was tested. Undiluted overnight grown fungi were spread on MHA plates. A 1:10 dilution of bacteria (100 μL of ∼1 × 10) in MHB broth was used. 8 The fungal infections (CFU / mL) were spread onto different MHA plates. 10 μL of MM8 and chlorhexidine gluconate 0.12% mouthwash were spotted onto the MHA plates containing fungi and the plates were incubated at 28°C for 24-48 hours. 10 μL of MM8 and chlorhexidine gluconate 0.12% mouthwash were spotted onto the MHA plates containing bacteria and the plates were incubated at 37°C for 24-48 hours.
[0116] The toxicity of MM8 in mammalian cells was compared to that of chlorhexidine gluconate 0.12% mouthwash using HeLa cells. HeLa cells were grown at 37°C in a 5% CO2 humidified incubator. HeLa cells were plated in 96-well plates at a cell density of 4000 cells / well in DMEM containing 1% penicillin / streptomycin and 10% fetal bovine serum (FBS). Cells were treated with MM8 or chlorhexidine gluconate 0.12% mouthwash at compound concentrations of 0.004%, 0.008%, 0.016%, 0.0310%, 0.0625%, 0.125%, 0.25%, 0.5%, and 1% v / v. Cells were incubated with compounds for 48 hours. Cell viability after 48 hours of incubation was assessed using MTT. MTT (5 mg / mL) was added to each well at 10% of the final volume and incubated for 2 hours at 37° C. in a 5% CO 2 incubator, and absorbance was read at 595 nm after solubilization in 100 μL of DMSO.
[0117] Figure 32 shows the toxicity of chlorhexidine gluconate 0.12% mouthwash on HeLa cells. The chlorhexidine gluconate 0.12% mouthwash had an IC 50 (G.I. 50 Figure 33 shows the toxicity of MM8 to HeLa cells. MM8 had an IC 50 (G.I. 50 Table 12 shows the GI 50 The percentages (%v / v) and SD are shown. [Table 12]
[0118] MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System were tested against antibiotic-susceptible and antibiotic-resistant fungal pathogens. Candida albicans, drug-resistant Candida parapsilosis (CDC 0339), drug-resistant C. auris (CDC 0383), multidrug-resistant C. auris (CDC 0385), C. tropicalis (CDC 0345), C. haemulonii (CDC 0393), C. glabrata (CDC 0315), C. duobushaemulonii (CDC 0394), Candida krusei (CDC 0397), Cryptococcus neoformans (H99), and Cryptococcus gattii (K265) were grown in YM medium for 24–48 h at 37°C. Trichophyton rubrum was grown in YM medium for 21 days at 30°C, and Aspergillus niger was grown for 5 days at 30°C. Approximately 1 × 10 8 CFU / mL of each culture was spread onto 100×15 mm square petri dishes containing MHA. Once the lawn of each fungal strain was spread, 10 μL of MM8 was spotted onto each area of the inoculated MHA plate, and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto different areas of the plate to test the efficacy of the formulations in killing the fungal strains (incubation at 37° C. for 48 hours for Candida and Cryptococcal species, at 28° C. for 30 days for T. rubrum, and at 28° C. for 7 days for A. niger).
[0119] Table 13 shows that MM8 killed all 12 strains of antibiotic-susceptible and antibiotic-resistant fungal pathogens. Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System all killed T. rubrum. Monistat® 3 killed 8 of the 12 antibiotic-susceptible and antibiotic-resistant fungal pathogens. "+" indicates complete clearing antifungal activity; "-" indicates no antifungal activity.
[0120] [Table 13]
[0121] a. Candida albicans (ATCC 26555) A solution of MM8 was prepared in water (10 mM DTPA, 1 mM CTAC, 25 μg / mL PMB). To six wells containing agar, 500 μL of water (control) or MM8 solution was added. Plates were incubated at 37 °C for 5 days. The water and MM8 solution were removed from the wells. A 1:10 diluted lawn of Candida albicans (~1 x 10 7 CFU / mL) were added to the wells. Plates were incubated at 37°C for 5 days. Panel A of Figure 34 shows that wells treated with water showed no protection from C. albicans, whereas wells treated with MM8 showed residual protection. A similar assay was performed with multidrug-resistant C. auris (CDC 0385); wells treated with water showed no protection from C. auris, whereas wells treated with MM8 showed residual protection from fungal growth.
[0122] A lawn of Candida albicans diluted 1:10 (~1 x 10 in 50 µL) 7CFU / mL) were spread onto agar plates. Plates were incubated at 37°C for 2 days. Plates were then treated with 500 μL of water (control) or MM8 solution for 5 minutes. Treatment was removed and plates were incubated at 37°C for an additional 3 days. Treated areas were each swabbed and inoculated onto new MHA plates to test for the presence of viable cells.
[0123] The top left panel of panel B of Figure 34 shows that wells pre-treated with water and inoculated with C. albicans had no residual protection from the fungus. The top right panel of panel B of Figure 34 shows that wells pre-treated with MM8 and inoculated with C. albicans showed residual protection from the fungus. The bottom left panel of panel B of Figure 34 shows that MHA plates infected with C. albicans and treated with water showed no protection against the fungus. The bottom right panel of panel B of Figure 34 shows that MHA plates infected with C. albicans and treated with MM8 showed protection against the fungus. Similar results were obtained when evaluating with C. auris (CDC 0385). Panel C of Figure 34 shows that MHA plates infected with C. auris and treated with MM8 showed protection against C. auris.
[0124] MHA plates were swabbed with C. albicans and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure. C. albicans (ATCC 26555) or C. auris (CDC 0385) were grown in YM medium for 24 hours at 37°C. Lawns of 1:10 diluted C. albicans or C. auris (~100 µL of ~1 x 10 7CFU / mL) was spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0125] Panel A of FIG. 35 shows that MM8 and Monistat® 3 killed Candida albicans, but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not. Circles encircle the clearance diameter of MM8. Panel B of FIG. 35 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat Candida albicans. FIG. 36 shows that treatment with Monistat® 3 Complete System resulted in colony invasion at the edge of the clearance diameter, resulting in a smaller clearance diameter than MM8.
[0126] b. Multidrug-resistant C. auris (CDC 0385) MHA plates were swabbed with multidrug-resistant C. auris (CDC 0385) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System. Multidrug-resistant Candida auris (CDC0385) was grown in YM medium for 24 hours at 37 °C. A lawn of 1:10 diluted C. auris (~100 µL of ~1 x 10 7CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM8 and spotted with approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0127] Panel A of FIG. 37 shows that MM8 and Monistat® 3 killed multi-resistant C. auris (CDC 0385), while Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant C. auris (CDC 0385). Circles enclose the clearance diameter produced by treatment with MM8. Panel B of FIG. 37 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems when used to treat multi-resistant C. auris (CDC 0385). MM8 was the only formulation with a clearance diameter.
[0128] c. Candida krusei (CDC 0397) MHA plates were swabbed with Candida krusei (CDC 0397) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System. Candida krusei (CDC0397) was grown in YM medium for 48 hours at 37°C. A lawn of undiluted Candida krusei (~100 μL of ~1 × 10 7CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 72 hours of incubation at 37° C.
[0129] Panel A of FIG. 38 shows that MM8 and Monistat® 3 killed Candida krusei (CDC 0397), while Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida krusei (CDC 0397). The circles enclose the clearance diameter produced by treatment with MM8. Panel B of FIG. 38 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems when used to treat multi-resistant C. auris (CDC 0385). MM8 was the only formulation that had a clearance diameter. FIG. 39 shows that treatment with the Monistat® 3 complete system resulted in colony invasion at the edge of the clearance diameter, resulting in a smaller clearance diameter than MM8.
[0130] d. Candida glabrata (CDC 0315) MHA plates were swabbed with Candida glabrata (CDC 0315) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure. Candida glabrata (CDC0315) was grown in YM medium for 24 hours at 37°C. A lawn of Candida glabrata (~1 × 10) diluted 1:10 was added to the plate. 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0131] Panel A of FIG. 40 shows that MM8 and Monistat® 3 Complete System killed Candida glabrata (CDC 0315), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida glabrata (CDC 0315). The circles enclose the diameter of the clearance created by treatment with MM8. Panel B of FIG. 40 shows a comparison of the diameter of clearance (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat multi-resistant Candida glabrata (CDC 0315).
[0132] e. Candida haemulonii (CDC 0393) MHA plates were swabbed with Candida haemulonii (CDC 0393) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System. Candida haemulonii (CDC0393) was grown in YM medium for 24 hours at 37°C. A lawn of 1:10 diluted Candida haemulonii (~100 μL of ~1 x 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0133] Panel A of FIG. 41 shows that MM8 and Monistat® 3 Complete System killed Candida haemulonii (CDC 0393), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill multi-resistant Candida haemulonii (CDC 0393). The circles enclose the diameter of the clearance created by treatment with MM8. Panel B of FIG. 41 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat multi-resistant Candida haemulonii (CDC 0393). MM8 and Monistat® 3 Complete System had similar clearance diameter (mm).
[0134] f. Candida duobuschaemulonii (CDC 0394) MHA plates were patched with Candida duobshaemulonii (CDC 0394) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure. Candida duobshaemulonii (CDC0394) was grown in YM medium for 48 hours at 37°C. A lawn of undiluted Candida duobshaemulonii (~100 μL of ~1 × 10 7 CFU / mL) was spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates, and approximately 10 μL drops of Lotrimin® Ultra, Tinactin®, Lamisil®, and Monistat® 3 complete systems were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 72 hours of incubation at 37° C.
[0135] Panel A of FIG. 42 shows that MM8, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System killed Candida duobschaemulonii (CDC 0394), while Lotrimin® Ultra Athlete's Foot Cream and Tinactin® Athlete's Foot Cream did not kill Candida duobschaemulonii (CDC 0394). The circles enclose the diameter of the clearance created by treatment with MM8. Panel B of FIG. 42 shows a comparison of the diameter of clearance (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat Candida duobschaemulonii (CDC 0394).
[0136] g. Candida tropicalis (CDC 0345) MHA plates were swabbed with Candida tropicalis (CDC 0345) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure System. Candida tropicalis (CDC0345) was grown in YM medium for 24 hours at 37°C. A 1:10 diluted lawn of Candida tropicalis (~100 μL of ~1 x 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0137] Panel A of FIG. 43 shows that MM8 and Monistat® 3 Complete System killed Candida tropicalis (CDC 0345), while Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Candida tropicalis (CDC 0345). The circles enclose the clearance diameter produced by treatment with MM8. Panel B of FIG. 43 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat Candida tropicalis (CDC 0345). MM8 was the only formulation that had a clearance diameter. FIG. 44 shows that treatment with Monistat® 3 complete system resulted in colony invasion at the edge of the clearance diameter, resulting in a clearance diameter of zero mm.
[0138] h. Aspergillus niger MHA plates were swabbed with A. niger and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Derman® Antifungal Cream. A. niger was grown in YM medium for 5 days at 30°C. A lawn of undiluted A. niger (~100 μL of ~1 × 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 5 days of incubation at 30° C.
[0139] Panel A of FIG. 45 shows that MM8, Lamisil® Athlete's Foot Cream, and Derman® Antifungal Cream killed A. niger, but Lotrimin® Ultra Athlete's Foot Cream and Tinactin® Athlete's Foot Cream did not. The circles enclose the diameter of the clearance created by treatment with MM8. Panel B of FIG. 45 shows a comparison of the diameter of the clearance (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Derman® Antifungal Cream when used to treat A. niger. MM8 had a larger diameter of clearance than Lamisil® Athlete's Foot Cream and Derman® Antifungal Cream.
[0140] i. Cryptococcus neoformans (H99) MHA plates were swabbed with Cryptococcus neoformans (H99) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure. Cryptococcus neoformans (H99) were grown in YM medium for 48 hours at 37 °C. A lawn of 1:10 diluted Cryptococcus neoformans (~100 µL of ~1 x 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0141] Panel A of FIG. 46 shows that MM8 and Monistat® 3 killed Cryptococcus neoformans (H99), but Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Cryptococcus neoformans (H99). The circles enclose the clearance diameter produced by treatment with MM8. Panel B of FIG. 46 shows a comparison of the clearance diameter (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 complete systems when used to treat Cryptococcus neoformans (H99). MM8 had a larger clearance diameter than Lamisil® Athlete's Foot Cream and Derman® Antifungal Cream.
[0142] j. Cryptococcus gattii (K265) MHA plates were swabbed with Cryptococcus gattii (K265) and treated with MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure. Cryptococcus gattii (K265) was grown in YM medium for 48 hours at 37 °C. A lawn of 1:10 diluted Cryptococcus gattii (~100 µL of ~1 x 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 48 hours of incubation at 37° C.
[0143] Panel A of FIG. 47 shows that MM8 and Monistat® 3 Complete System killed Cryptococcus gattii (K265), while Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Lamisil® Athlete's Foot Cream did not kill Cryptococcus gattii (K265). The circles enclose the diameter of the clearance created by treatment with MM8. Panel B of FIG. 47 shows a comparison of the diameter of clearance (mm) of MM8, Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete System when used to treat Cryptococcus gattii (K265). K. Geomyces destructans (ATCC MYA4855) MHA plates were inoculated with Geomyces destructans, the bat pathogen responsible for white-nose syndrome, and treated with MM8. Geomyces destructans were grown in YM medium for 30 days at 8 °C. A lawn of undiluted Geomyces destructans (~100 μL of ~1 × 10 6 The fungal killing efficacy of MM8 was tested after a 7-day incubation period at 8° C. by spotting 10 μL of MM8 onto the inoculated MHA plates. Figure 48 shows that MM8 killed Geomyces destructans. The circles enclose the diameter of the clearance created by treatment with MM8.
[0144] l. Trichophyton rubrum (ATCC 28188) MHA plates were inoculated with T. rubrum and treated with MM8, Lamisil® Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lotrimin® Ultra Athlete's Foot Cream, and Derman® Antifungal Cream. T. rubrum was grown in YM medium for 30 days at 30°C. Lawns of undiluted T. rubrum (~1 × 10 7 CFU / mL) were spread onto MHA plates. 10 μL of MM8 was spotted onto the inoculated MHA plates and approximately 10 μL drops of Lotrimin® Ultra Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, Lamisil® Athlete's Foot Cream, and Monistat® 3 Complete Cure were spotted onto the MHA plates to test the fungus-killing efficacy of the formulations after 6 days of incubation at 28° C.
[0145] Panel A of FIG. 49 shows that MM8, Lamisil® Athlete's Foot Cream, Tinactin® Athlete's Foot Cream, and Derman® Antifungal Cream killed T. rubrum. Lamisil® Athlete's Foot Cream was the most effective at killing T. rubrum. At higher concentrations (i.e., 10X concentration), MM8 was as effective as Lamisil® at killing T. rubrum. The circle encircles the diameter of the clearance created by treatment with MM8. Panel B of FIG. 49 shows that MM8 was as effective as chlorhexidine gluconate 0.12% mouthwash at killing T. rubrum. The circle encircles the diameter of the clearance created by treatment with MM8.
[0146] Example 6 Antibacterial efficacy of MM8 MM8 was used to test the efficacy of the formulations in killing drug-resistant and drug-susceptible bacteria. Mupirocin, bacitracin, neomycin, and triple antibiotics were used as comparisons. The formulations were used to test the killing efficacy against vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant carbapenem-resistant Enterobacteriaceae (CRE NDM-1 MDR), multidrug-resistant Acinetobacter baumannii, multidrug-resistant Pseudomonas aeruginosa, Escherichia coli (O157:H7), Stenotrophomonas maltophilia, Mycobacterium abscessus, Streptococcus pyogenes, and Burkholderia cepacia.
[0147] Vancomycin-resistant Enterococcus (VRE) (ATCC 51299), Methicillin-resistant Staphylococcus aureus (MRSA) (ATCC BAA44), multidrug-resistant carbapenem-resistant Enterobacteriaceae (CRE NDM-1 MDR) (ATCC BAA 2146), multidrug-resistant Acinetobacter baumannii (ATCC 1797), multidrug-resistant Pseudomonas aeruginosa (ATCC 2114), Escherichia coli (O157:H7) (ATCC 51657), Stenotrophomonas maltophilia (ATCC 13637), Streptococcus pyogenes, and multidrug-resistant Burkholderia cepacia (ATCC 10856) or non-pathogenic E. pestis (Cymo 6) were grown overnight at 37°C in Mueller-Hinton broth. Mycobacterium abscessus was grown in Middlebrook 7H9 broth and incubated for 48 h at 37°C. Each bacterial strain was diluted 1:10 (~1 × 10 in ~100 μL) with the exception of VRE and S. maltophilia. 8 CFU / mL) were plated onto MHA plates and tested for killing efficacy after initially treating with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 24-48 hours and then evaluated.
[0148] Table 14 shows that MM8 killed 10 antibiotic-susceptible and antibiotic-resistant Gram-positive and Gram-negative bacterial strains tested. "+" indicates complete clearing antibacterial activity; "-" indicates no antibacterial activity. [Table 14]
[0149] a. Yesenia pestis (Cymo 6) Non-pathogenic cytoplasmic E. pestis (~1 x 10 in ~100 µL) 9Undiluted cultures of 10 ...
[0150] Panel A of Figure 50 shows circles around the diameter of clearance produced by treatment with MM8, indicating that mupirocin and neomycin were more effective than MM8, but MM8 was more effective than bacitracin and triple antibiotic ointment after a 1-day incubation period. Panel B of Figure 50 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash were approximately equally toxic to E. pestis (Cymo 6).
[0151] b. Vancomycin-resistant Enterococcus (VRE) (ATCC 51299) MHA plates were patched with VRE and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 6 days and the clearance diameter of each formulation was measured. Undiluted cultures of VRE (~100 μL of ~1 x 10 9 CFU / mL) were plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37° C. for an initial period of 24 hours, followed by an additional 6-day incubation to address the long-term killing efficacy of MM8.
[0152] Panel A of Figure 51 shows that MM8 and bacitracin killed VRE after one day of incubation. The circles enclose the diameter of clearance produced by treatment with MM8, showing that MM8 was the most effective treatment compared to mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Panel B of Figure 51 shows that after seven days of incubation, the area of VRE treated with MM8 was the only remaining diameter of clearance, indicating that a single treatment with MM8 had a long-lasting effect on VRE.
[0153] C. Methicillin-resistant Staphylococcus aureus (MRSA) MHA plates were patched with MRSA and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 3 days and the clearance diameter of each formulation was measured. Cultures of MRSA (ATCC BAA44) were diluted 1:10 (~1 x 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 24 hours, followed by an additional 3-day incubation to address the long-term killing efficacy of MM8. Panel A of Figure 52 shows that MM8 and mupirocin killed MRSA after one day of incubation time. The circle encircles the diameter of clearance produced by treatment with MM8. Panel B of Figure 52 shows that after four days of incubation, MM8 and mupirocin was the best formulation that killed MRSA. No regrowth of MRSA killed by mupirocin and MM8 was observed.
[0154] d. Multidrug-resistant Carbapenem-resistant Enterobacteriaceae (CRE NDM-1 MDR) MHA plates were patched with CRE NDM-1 MDR and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 4 days and the clearance diameter of each formulation was measured. Cultures of CRE NDM-1 MDR were inoculated 1:10 (~1x10 8 CFU / mL) and ~100 μL was plated on MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 24 hours, followed by an additional 4-day incubation to address the long-term killing efficacy of MM8.
[0155] Panel A of Figure 53 shows that MM8 and mupirocin killed CRE NDM-1 MDR after 1 day of incubation. The circle encloses the diameter of clearance produced by treatment with MM8. Panel B of Figure 53 shows that after 5 days of incubation, MM8 and mupirocin were the best formulations that killed CRE NDM-1 MDR. No regrowth of CRE NDM-1 MDR killed by mupirocin and MM8 was observed.
[0156] e. Multidrug-resistant Acinetobacter baumannii (ATCC 1797) MHA plates were inoculated with multidrug-resistant Acinetobacter baumannii and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37 °C for 1 day, and the clearance diameter of each formulation was measured. Cultures of A. baumannii were diluted 1:10 (~1 × 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment to test the efficacy of the formulations in killing A. baumannii after 24 h incubation at 37°C. Figure 54 shows that MM8 and mupirocin killed A. baumannii after a 1 day incubation period. The circle encloses the diameter of the clearance produced by treatment with MM8. f. Multidrug-resistant Pseudomonas aeruginosa (ATCC 2114) MHA plates were inoculated with multidrug-resistant P. aeruginosa and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Cultures of P. aeruginosa were diluted 1:10 (~1 × 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment to test the efficacy of the formulations in killing P. aeruginosa after 24 h incubation at 37°C. Figure 55 shows that MM8 and mupirocin killed multidrug-resistant P. aeruginosa after a 1-day incubation period. The circle encloses the diameter of clearance produced by treatment with MM8.
[0157] g. Escherichia coli (O157:H7) (ATCC 51657) MHA plates were patched with E. coli (O157:H7) and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 4 days and the clearance diameter of each formulation was measured. Cultures of E. coli O157:H7 (ATCC 51657) were diluted 1:10 (~1 x 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, and 10 μL of mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto the MHA plates to test the efficacy of the formulations in killing E. coli after 24 hours of incubation at 37°C and an additional 4 days of incubation.
[0158] Panel A of Figure 56 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed E. coli (O157:H7) after one day of incubation. The circles enclose the diameter of clearance produced by treatment with MM8. Panel B of Figure 56 shows that after five days of incubation, MM8, mupirocin, neomycin, and triple antibiotic ointment were the best formulations that killed E. coli (O157:H7). No regrowth of E. coli (O157:H7) killed by MM8, mupirocin, neomycin, and triple antibiotic ointment was observed.
[0159] h. Multidrug-resistant Burkholderia cepacia (ATCC 10856) MHA plates were patched with multidrug-resistant Burkholderia cepacia and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 3 days and the clearance diameter of each formulation was measured. Cultures of B. cepacia were diluted 1:10 (~1 × 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, and 10 μL of mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto the MHA plates and incubated at 37°C for 24 hours, and the formulations were tested for their efficacy in killing B. cepacia after an additional 3 days of incubation.
[0160] Panel A of Figure 57 shows that MM8 was the only formulation that killed multidrug-resistant Burkholderia cepacia after one day of incubation. The circle encircles the diameter of clearance produced by treatment with MM8. Panel B of Figure 57 shows that after four days of incubation, MM8 was the only formulation that killed multidrug-resistant Burkholderia cepacia. No regrowth of multidrug-resistant Burkholderia cepacia killed by MM8 was observed. i. Streptococcus pyogenes MHA plates were inoculated with S. pyogenes and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Plates were then incubated at 37°C for an additional 6 days and the clearance diameter of each formulation was measured. Cultures of S. pyogenes were diluted 1:10 (~1 x 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, and 10 μL of mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto the MHA plates to test the efficacy of the formulations in killing S. pyogenes after 24 h incubation at 37°C and an additional 6 days of incubation.
[0161] Panel A of Figure 58 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed S. pyogenes after one day of incubation. The circle encircles the diameter of clearance produced by treatment with MM8. Panel B of Figure 58 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment further killed S. pyogenes after seven days of incubation. Figure 59 shows that S. pyogenes colonies invaded the neomycin and triple antibiotic treated areas, while the MM8 treated areas showed no regrowth of S. pyogenes colonies.
[0162] j. Polymyxin E-resistant Stenotrophomonas maltophilia (ATCC 13637) MHA plates were stained with polymyxin E (PME)-resistant Stenotrophomonas maltophilia and treated with MM8 and, alternatively, MM8 prepared with Ca-DTPA. Plates were incubated at 37 °C for 1 day and the clearance diameter of each formulation was measured. Cultures of polymyxin E-resistant S. maltophilia (ATCC 13637), previously rendered resistant to PME in the laboratory, were prepared by growing a culture of S. maltophilia in 100 μg / mL PME overnight at 37 °C and diluting it. Approximately 100 μL of a 1:10 dilution (~1 × 10 8 CFU / mL) were plated on MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 to test the efficacy of the formulations in killing S. maltophilia after 24 h incubation at 37°C. Figure 60 shows that MM8 killed polymyxin E resistant Stenotrophomonas maltophilia after one day of incubation. The circles enclose the diameter of clearance produced by treatment with MM8.
[0163] k. Bacillus subtilis (ATCC 6633) MHA plates were plated with B. subtilis and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. Cultures of B. subtilis were diluted 1:10 (~1 × 10 8 CFU / mL), ~100 μL was plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, and 10 μL of mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto the MHA plates to test the efficacy of the formulations in killing B. subtilis after 24 h incubation at 37°C. Figure 61 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed B. subtilis after a 1 day incubation period. The circles enclose the diameter of clearance produced by treatment with MM8.
[0164] l. Mycobacterium abscessus (ATCC 19977) MHA plates were inoculated with Mycobacterium abscessus and treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. Plates were incubated at 37 °C for 2 days and the clearance diameter of each formulation was measured. Approximately 100 μL of undiluted culture of M. abscessus (~1 × 10 9 CFU / mL) were plated onto MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, and 10 μL spots of mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto the MHA plates to test the efficacy of the formulations in killing M. abscessus after 48 hours of incubation at 37° C. The MHA plates were then stained with MTT (blue-black) to visualize colony growth.
[0165] Panel A of Figure 62 shows that MM8 was the only formulation that killed M. abscessus. The circle encircles the diameter of the clearance created by treatment with MM8. The plate was sprayed with a solution of 5mg / mL MTT which turns only viable cells purple. The MM8 treated area of the plate appeared clear / yellow indicating zero viability. In contrast, the surrounding plate area was blue / black indicating metabolic activity and cell survival. Panel B of Figure 62 shows an image of MHA stained with MTT. The image shows that there was no colony regrowth in the MM8 treated area.
[0166] m.MRSA BAA-1717 (USA 300) and multidrug-resistant Burkholderia cepacia (ATCC 10856) An overnight growth of MRSA BAA-1717 (USA 300) was diluted 1:10 (1 × 10 8 CFU / mL) and plated on MHA plates. Overnight growths of multidrug-resistant Burkholderia cepacia were diluted 1:10 (1 × 10 8CFU / mL) were plated onto a second MHA plate. The MHA plate was treated with 10 μL of MM8, mupirocin, bacitracin, neomycin, and triple antibiotic ointment. The plates were incubated overnight at 37° C. and the clearance diameter of each formulation was measured. Panel A of Figure 63 shows that MM8 and mupirocin killed MRSA BAA-1717 (USA 300). The circle encircles the diameter of clearance produced by treatment with MM8. Panel B of Figure 63 shows that MM8, mupirocin, neomycin, and triple antibiotic ointment killed multidrug-resistant Burkholderia cepacia.
[0167] Example 7 Bactericidal properties of MM8 MHA plates were plated with MRSA BAA-1717 (USA 300), MRSA BAA-44, Acinetobacter baumannii (ATCC 1797), Pseudomonas aeruginosa (ATCC 2114), multidrug-resistant C. auris, and multidrug-resistant Burkholderia cepacia. MHA plates were treated with MM8 and chlorhexidine gluconate 0.12% mouthwash. Plates were incubated at 37°C for 1 day and the clearance diameter of each formulation was measured. MRSA BAA-1717 (USA 300), MRSA BAA-44, Acinetobacter baumannii (ATCC 1797), Pseudomonas aeruginosa (ATCC 2114), multidrug-resistant C. auris, and multidrug-resistant Burkholderia cepacia (ATCC 10856) were grown overnight at 37°C in Mueller-Hinton broth. Bacterial cultures were diluted 1:10 (~1 × 10 8 CFU / mL), plated on MHA plates with ~100 μL of undiluted culture of Candida albicans (~1 × 10 8 CFU / mL) were plated on MHA plates. The inoculated MHA plates were treated with 10 μL of MM8 and 10 μL of chlorhexidine gluconate 0.12% mouthwash to test the efficacy of the formulations in killing bacteria after 24 hours of incubation at 37°C.
[0168] Panel A of Figure 64 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed MRSA BAA-1717 (USA 300). Panel B of Figure 64 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed MRSA BAA-44. Panel A of Figure 65 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Acinetobacter baumannii (ATCC 1797). Panel B of Figure 65 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Pseudomonas aeruginosa (ATCC 2114). Panel A of Figure 66 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed multidrug-resistant Burkholderia cepacia. Panel B of Figure 66 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed multidrug-resistant C. auris. The circles indicate the diameter of the clearance produced by treatment with MM8 after a 1-day incubation time.
[0169] MHA plates were patched with Candida albicans and a multidrug-resistant Candida panel from the Centers for Disease Control (CDC). MHA plates were treated with MM8 and chlorhexidine. Plates were incubated at 37°C for 2 days and the clearance diameter of each formulation was measured. Candida albicans (ATCC 26555) and a multidrug-resistant Candida panel from the CDC were grown in YM medium for 24-48 hours at 37°C. Approximately 100 μL of lawn (~1 × 10) of undiluted Candida spp. was stained with MM8 and chlorhexidine. Plates were incubated at 37°C for 2 days and the clearance diameter of each formulation was measured. 8 CFU / mL) were spread onto MHA plates. The inoculated MHA plates were spotted with 10 μL of MM8 and 10 μL of chlorhexidine gluconate 0.12% mouthwash to test the efficacy of the formulations in killing the Candida panel after 48 hours of incubation at 37°C.
[0170] Panel A of Figure 67 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Candida albicans (ATCC 26555). Panel B of Figure 67 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed C. auris (CDC 0383) after 2 days of incubation. Panel A of Figure 68 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Candida tropicalis (CDC 0345) after 2 days of incubation. Panel B of Figure 68 shows that MM8 and chlorhexidine gluconate 0.12% mouthwash killed Candida glabrata (CDC 0315) after 2 days of incubation. Panel A of Figure 69 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida haemulonii (CDC 0393) after 2 days of incubation. Panel B of Figure 69 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida duobushaemulonii (CDC 0339) after 2 days of incubation. Panel A of Figure 70 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida parapsilosis (CDC 0339) after 2 days of incubation. Panel B of Figure 70 shows that MM8 and chlorhexidine gluconate 0.12% rinse killed Candida krusei (CDC 0397) after 2 days of incubation. The circles indicate the diameter of the clearance created by treatment with MM8.
[0171] The bactericidal properties of MM8 against Cryptococcus gattii, Cryptococcus neoformans, and Aspergillus niger were also tested. Cryptococcus gattii (K265) and Cryptococcus neoformans (H99) were grown in YM medium for 24–48 h at 37 °C, and Aspergillus niger was grown in YM medium for 5 days at 30 °C. Approximately 100 μL of lawns (~1 × 10) of undiluted Cryptococcus gattii, Cryptococcus neoformans, and Aspergillus niger were added to the MM8 solution. 8CFU / mL) were spread onto MHA plates. 10 μL of MM8 and 10 μL of chlorhexidine gluconate 0.12% mouthwash were spotted onto the inoculated MHA plates to test the efficacy of the formulations in killing Cryptococcus gattii (K265) and Cryptococcus neoformans (48 h incubation at 37°C) and Aspergillus niger (5 days incubation at 28°C).
[0172] Panel A of Figure 71 shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed Cryptococcus gattii. Panel B of Figure 71 shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed Cryptococcus neoformans. Panel A of Figure 72 shows the front side of an MHA plate infected with A. niger and shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed A. niger. Panel B of Figure 72 shows the back side of an MHA plate infected with A. niger and shows that MM8 and a 0.12% chlorhexidine gluconate rinse killed A. niger.
[0173] Example 8 Effect of treatment with MM1 and MM8 on fungal and bacterial biofilms The efficacy of MM1 and MM8 in killing fungal biofilms was tested using S. epidermidis (ATCC 35984), C. auris, and C. albicans biofilms. C. albicans (ATCC 26555) and C. auris (CDC 0385) were grown overnight at 37°C in 1:10 YM medium (10% YM medium and 90% sterile water). Cultures were diluted 1:100 in 10% Mueller-Hinton broth and 90% sterile water. Diluted C. albicans and C. auris were plated in a volume of 100 μL into 96-well TC-treated plates and the plates were incubated at 37°C in a non-shaking incubator. After 24 hours of incubation, the medium was removed and replaced with 1:10 YM, and the plates were incubated at 37°C for an additional 24 hours. After the second day of incubation, the medium was removed and the wells were washed three times with 1:10YM and then treated with 100 μL of 100 μM PAO (positive killing control), water (positive growth control), chlorhexidine gluconate 0.12% mouthwash, MM8, MM8 without polymyxin B, and MM1 for 15 minutes at 37° C. All treatments were removed and 100 μL of 1:10YM was added. The plates were incubated at 37° C. for an additional three days. The wells were washed three times with 1:10YM and 100 μL of a 5 mg / ml solution of MTT was added to the wells. The plates were incubated overnight at 37° C. The following day, all MTT was removed and replaced with solubilization solution. Cell viability was assessed by reading the optical density at 595 nm as a measure of treatment efficacy.
[0174] Staphylococcus epidermidis (ATCC 35984) was grown overnight at 37° C. in 1:10 MHB (10% Mueller-Hinton broth and 90% sterile water). The culture was diluted 1:100 in 10% Mueller-Hinton broth and 90% sterile water. The diluted S. epidermidis cells were plated in a volume of 100 μL into 96-well TC-treated plates and the plates were incubated at 37° C. in a non-shaking incubator. After 24 hours of incubation, the medium was removed and replaced with 1:10 MHB, and the plates were incubated at 37° C. for an additional 24 hours. After the second day of incubation, the medium was removed and the wells were washed three times with 1:10 MHB, then treated with 100 μL of 100 μM PAO (positive killing control), water (positive growth control), chlorhexidine gluconate 0.12% mouthwash, MM8, MM8 without polymyxin B, and MM1 for 15 minutes at 37° C. All treatments were removed and 100 μL of 1:10 MHB was added. The plates were incubated at 37° C. for an additional three days. The wells were washed three times with 1:10 MHB, and 100 μL of a 5 mg / ml solution of MTT was added to the wells. The plates were incubated overnight at 37° C. The following day, all MTT was removed and replaced with solubilization solution. Optical density was read at 595 nm to assess cell viability as a measure of treatment efficacy.
[0175] FIG. 73 shows that chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8 were equally effective on pre-established S. epidermidis biofilms after 15 minutes of treatment. Panel A of FIG. 74 shows the colorimetric results of treating 8-day-old biofilms of C. auris with PAO, no treatment, chlorhexidine gluconate 0.12% mouthwash, MM7, or MM8. Panel B of FIG. 74 shows that chlorhexidine gluconate 0.12% mouthwash, MM7, and MM8 were most effective at killing pre-established multi-drug resistant C. auris biofilms. Panel A of FIG. 75 shows the colorimetric results of treating 6-day-old biofilms of C. albicans with PAO, no treatment, chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8. Panel B of Figure 75 shows that chlorhexidine gluconate 0.12% mouthwash, MM1, and MM8 were the most effective at killing pre-established multidrug-resistant Candida albicans biofilms.
[0176] The bactericidal properties of MM8 against (dead) chicken skin infected with Bacillus subtilis (ATCC 6633) were tested. Skin was removed from store-bought chicken thighs, washed, and inoculated with 500 μL of Bacillus subtilis culture (~1 × 10 9 Skin samples were infected with 1000 μl of water (CFU / mL). Bacteria were rubbed into the skin samples for 15 seconds and remaining liquid was wiped off with paper towels. Skin samples were cut in half and one piece was treated with water and the second piece with various concentrations of MM8. Treatment with water or MM8 was followed by a 15 second skin rub and then a 20 minute incubation at room temperature. 200 μl of water was applied to each skin sample, rubbed in and collected. 10 μl of water was spread onto MHA plates and incubated overnight at 37°C.
[0177] Panel A of Figure 76 shows chicken skin samples infected with Bacillus subtilis and disinfected with concentrated MM8. Panel B of Figure 76 shows colony counts after treatment with water (top) and 5x concentrated MM8 (bottom). Panel C of Figure 76 shows colony counts after treatment with water (top) or 2x concentrated MM8 (bottom). Panel D of Figure 76 shows colony counts after treatment with water (top) or 1x MM8 (bottom).
[0178] Cultures of MRSA BAA-44 and multidrug-resistant Acinetobacter baumannii (ATCC 1797) were grown overnight or for 24 h at 37 °C in Mueller-Hinton broth or YM medium. 100 μL of undiluted bacterial culture (~1 × 10 9 CFU / mL) were plated on MHA plates. To test the efficacy of the formulations to kill A. baumannii after 24 hours of incubation, the inoculated MHA plates were treated with 10 μL of 1) MM8 or chlorhexidine gluconate 0.12% mouthwash; or 2) MM8 or chlorhexidine gluconate 0.12% mouthwash with 20% fetal bovine serum. Panel A of Figure 77 shows that 20% FBS did not reduce the efficacy of MM8 or chlorhexidine gluconate 0.12% mouthwash on gram-positive MRSA. Panel B of Figure 77 shows that 20% FBS did not reduce the efficacy of MM8 to kill gram-negative multidrug-resistant A. baumannii, but 20% FBS reduced the efficacy of chlorhexidine gluconate 0.12% mouthwash on multidrug-resistant A. baumannii.
[0179] Example 9 Formulations containing MM8 and EDTA MM8 10 was formulated to contain MM8 and 10 mM ethylenediaminetetraacetic acid (EDTA). 100was formulated to contain MM8 and 100 mM EDTA. MHA plates were treated with multidrug-resistant Burkholderia cepacia, Acinetobacter baumannii (ATCC 1797), MRSA BAA-44, multidrug-resistant C. auris (CDC 0385), and Pseudomonas aeruginosa (ATCC 2114). MHA plates containing Acinetobacter baumannii (ATCC 1797), MRSA BAA-44, and multidrug-resistant C. auris (CDC 0385) were treated with MM8. 10 MHA plates containing multidrug-resistant C. auris (CDC 0385), P. aeruginosa (ATCC 2114), MRSA BAA-44, and multidrug-resistant Burkholderia cepacia were treated with MM8. 100 Plates were then incubated at 37°C for 1 day. Cultures of multidrug-resistant Burkholderia cepacia (ATCC 10856), Acinetobacter baumannii (ATCC 1797), MRSA BAA-44, multidrug-resistant C. auris (CDC 0385), and Pseudomonas aeruginosa (ATCC 2114) were grown overnight or for 24 hours at 37°C in Mueller-Hinton broth or YM medium. Approximately 100 μL of undiluted bacterial and Candida cultures (~1 × 10 9 The inoculated MHA plates were then plated with 10 μL of MM8 and 10 μL of MM8. 10 and the killing efficacy was tested after 24 hours incubation for bacterial plates and 48 hours incubation for C. auris at 37°C.
[0180] Panel A of Figure 78 shows the MM8 10 Panel B of Figure 78 shows that MM8 was less effective than MM8 alone in killing Acinetobacter baumannii (ATCC 1797). 10 Panel A of Figure 79 shows that MM8 was less effective than MM8 alone in killing MRSA BAA-44. 10 Panel B of Figure 79 shows that MM8 was less effective than MM8 alone in killing multidrug-resistant C. auris. 100was less effective than MM8 alone in killing multidrug-resistant C. auris. Panel A of Figure 80 shows the MM8 100 Panel B of Figure 80 shows that MM8 was more effective than MM8 alone in killing P. aeruginosa (ATCC 2114). 100 The results show that MM8 was more effective than MM8 alone in killing MMRSA BAA-44. 100 Improvements were observed in clearance diameter and marginal firmness in the areas treated with MM8. 100 were more effective than MM8 alone in killing Burkholderia cepacia (ATCC 10856).
[0181] Example 10 Comparison of hemolytic activity The hemolytic activity of chlorhexidine gluconate 0.12% mouthwash and MM8 was compared. 5 μL of CellLytic® B, chlorhexidine gluconate 0.12% mouthwash, or MM8 were spotted onto a standard blood agar plate. Hemolysis was allowed to continue for 6 hours at room temperature. Hemolysis results in lysis of red blood cells, and the hemolyzed areas on the blood agar plate appear yellow or clear. Figure 82 shows that CellLytic® B produced dramatic clearance, while chlorhexidine gluconate 0.12% mouthwash and MM8 did not affect the color of the plate. The data shows that MM8 was less hemolytic than chlorhexidine gluconate 0.12% mouthwash.
[0182] Example 11 Efficacy of the formulation against anaerobic oral and facial bacteria The efficacy of diluted MM1 and MM8 against anaerobic oral and facial bacteria was tested. Cultures of Propionibacterium acnes (ATCC 6919) and Streptococcus mutans (85W 2357) were grown in tryptic soy broth (TSB) medium containing 10% sheep blood. Cultures were incubated at 37 °C under anaerobic conditions for 4 days. Approximately 100 μL of undiluted bacterial culture (~1 × 10 9 CFU / mL) were plated on MHA plates. The inoculated MHA plates were treated with 10 μL of MM8, a 1:2 dilution of MM8 in water, and a 1:10 dilution of MM1. The plates were incubated at 37°C under anaerobic conditions for 11 days (P. acnes) or 2 days (S. mutans). Figure 83 shows that MM8, a 1:2 aqueous dilution of MM8, and a 1:10 aqueous dilution of MM1 were equally effective in killing the anaerobic bacteria Propionibacterium acnes (ATCC 6919) and Streptococcus mutans (85W 2357).
[0183] Example 12 Assessment of hemolysis in MM7 5 μL of cell lysis buffer (CLB; positive control), MM7 (MycoDelens), 4% benzoyl peroxide, 10% benzoyl peroxide, and 2% salicylic acid were spotted onto blood agar plates. The blood agar plates were refrigerated overnight and assessed for hemolysis. Clear areas on the plate indicated hemolysis. Figure 84 shows blood agar plates spotted with lysis buffer, MM7, 4% benzoyl peroxide, 10% benzoyl peroxide, and 2% salicylic acid. The data show that lysis buffer caused complete cell lysis, MM7 showed little to no hemolysis, benzoyl peroxide (4% and 10%) caused complete hemolysis, and 2% salicylic acid caused little to no hemolysis.
[0184] Example 13 Evaluation of the efficacy of MM7, MM8, MM12, and MM13 to kill MRSA BAA-44, multidrug-resistant A. baumannii (ATCC 1797), multidrug-resistant P. aeruginosa (ATCC 2114), and C. albicans Overnight growth of MRSA BAA-44, multidrug-resistant A. baumannii (ATCC 1797), multidrug-resistant P. aeruginosa (ATCC 2114), and C. albicans was performed on MHB. Each bacteria and yeast was spread undiluted onto a different MHA plate. 10 μL drops of MM7, MM8, MM12, MM13, and vehicle controls (25% ethanol in PG and 50% ethanol in PG) were spotted onto different areas of each MHA plate. The MHA plates were incubated overnight at 37°C and evaluated.
[0185] Panel A of Figure 85 shows MHA plates of MRSA BAA-44 treated with MM7, MM8, MM12, MM13, and vehicle control. Panel B shows MHA plates of A. baumannii treated with MM7, MM8, MM12, MM13, and vehicle control. Panel C shows MHA plates of P. aeruginosa treated with MM7, MM8, MM12, MM13, and vehicle control. Panel D shows MHA plates of C. albicans treated with MM7, MM8, MM12, MM13, and vehicle control. The data shows that treatment with MM7, MM8, MM12, and MM13 was able to kill MRSA BAA-44, multi-resistant A. baumannii, multi-resistant P. aeruginosa, and C. albicans (ATCC 26555) after one day of incubation time.
[0186] Example 14 Evaluation of efficacy of MM7, MM9, MM10, and MM11 against MRSA BAA-44, multidrug-resistant A. baumannii (ATCC 1797), multidrug-resistant P. aeruginosa (ATCC 2114), and C. albicans Overnight growth of MRSA, A. baumannii, P. aeruginosa, and C. albicans was performed in MHB. MRSA, A. baumannii, and P. aeruginosa samples were diluted 1:10, and C. albicans samples were used undiluted. Samples were spread on different MHA plates. 10 μL drops of MM7, MM9, MM10, and MM11 were spotted on different areas of each plate. Plates were incubated overnight at 37°C.
[0187] Panel A of Figure 86 shows MHA plates of A. baumannii treated with MM7, MM9, MM10, and MM11. Panel B shows MHA plates of MRSA BAA-44 treated with MM7, MM9, MM10, and MM11. Panel C shows MHA plates of P. aeruginosa treated with MM7, MM9, MM10, and MM11. Panel D shows MHA plates of C. albicans treated with MM7, MM9, MM10, and MM11. The data show that MM7, MM9, MM10, and MM11 were effective in killing MRSA BAA-44, multi-resistant A. baumannii, multi-resistant P. aeruginosa, and C. albicans after a 1-day incubation time. Overnight growth of MRSA BAA-44, multidrug-resistant A. baumannii (ATCC 1797), multidrug-resistant P. aeruginosa (ATCC 2114), and C. albicans was performed in MHB. MRSA BAA-44, multidrug-resistant A. baumannii, and multidrug-resistant P. aeruginosa were diluted 1:10, and C. albicans was used undiluted. Each bacterial strain was spread onto a different MHA plate. 10 μL drops of MM7, MM9, MM10, and MM11 were spotted onto different MHA plates. Plates were incubated overnight at 37°C and fogged with 5 mg / mL stock of MTT.
[0188] Panel A of Figure 87 shows MHA plates of MRSA BAA-44 treated with MM7, MM9, MM10, and MM11. Panel B shows MHA plates of A. baumannii (ATCC 1797) treated with MM7, MM9, MM10, and MM11. Panel C shows MHA plates of P. aeruginosa (ATCC 2114) treated with MM7, MM9, MM10, and MM11. Panel D shows MHA plates of C. albicans treated with MM7, MM9, MM10, and MM11. The data show that MM7, MM9, MM10, and MM11 were effective in killing MRSA BAA-44, multi-resistant A. baumannii, multi-resistant P. aeruginosa, and C. albicans after a 1-day incubation time.
[0189] (Example 16) Evaluating the efficacy of formulations of the present disclosure in killing colistin-resistant bacteria Overnight growth of MCR-1 E. coli (AR 0350) was performed in MHB and spread undiluted onto MHA plates. 10 μL drops of MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotic ointment were spotted onto different areas of the MHA plates. Plates were incubated at 37°C for 1 day. Figure 88 shows MHA plates of E. coli treated with MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotics. The data shows that only MM7, MM9, and mupirocin completely killed MCR-1 E. coli (AR 0350; colistin resistant only) after one day of incubation time. Overnight growth of multi-drug resistant E. coli (AR 0348) was performed in MHB. Samples were diluted 1:1000 and spread on MHA plates. 10 μL of MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotic cream were spotted on different areas of the MHA plates. Plates were incubated at 37°C for 1 day.
[0190] Figure 89 shows MHA plates of multi-drug resistant E. coli treated with MM7, MM9, mupirocin, bacitracin, neomycin, and triple antibiotic cream. The data shows that only MM7, MM9, and mupirocin completely killed the multi-drug resistant E. coli (AR 0348) after one day of incubation time. Overnight growth of multi-drug resistant E. coli (AR 0346) was performed in MHB. Samples were diluted 1:1000 and spread on MHA plates. 10 μL of MM8, mupirocin, bacitracin, neomycin, and triple antibiotic cream were spotted on different areas of the MHA plates. Plates were incubated at 37°C for 3 days. Figure 90 shows MHA plates of multi-resistant E. coli (AR 0346) treated with MM8, mupirocin, bacitracin, neomycin, and triple antibiotic cream. The data shows that only MM8 and mupirocin completely killed the multi-resistant E. coli (AR 0346) after a 3-day incubation period.
[0191] (Example 17) Evaluating the efficacy of formulations mixed with petrolatum MM12 was mixed with an equal volume of petrolatum (VaselineMD) until a suspension was formed. The MM12 / Vaseline mixture was applied to lawns of multi-resistant A. baumannii, MRSA BAA-44, or C. albicans by gently rubbing the MM12 / Vaseline mixture into the lawns. The efficacy of the formulation was evaluated after 24 hours. MM12 retained antibacterial and antifungal efficacy even when mixed with an equal volume of petrolatum. Petrolatum did not contribute to the toxicity observed with treatment of lawns with the MM12 / Vaseline mixture. Figure 91 shows the effect of the MM12 / Vaseline mixture (VaselineMD) and petrolatum on killing lawns infected with A. baumannii ATCC 1797, MRSA BAA-44, and C. albicans.
[0192] (Example 18) Evaluation of the disinfectant efficacy of MycoDelens using a time-kill kinetic assay. Overnight growths of bacteria were prepared in MHB or overnight growths of C. albicans were prepared in YM medium. To a 1.6 mL tube of sample, 100 μL of MHB, 100 μL of MM12-neutralizing blocking buffer, and 100 μL of MM12 were added sequentially. Then, 90 μL of blocking buffer and cells in 10 μL of MM12 were added to the tube at the appropriate time point. The resulting mixture was incubated at room temperature for 10 min. Approximately 1 × 10E 8 CFU / mL of cells were added to each tube. 10 μL samples were removed from the MycoDelens tubes at t=5 sec, 30 sec, or 2 min, and the samples were added to 90 μL of blocking buffer. Samples were incubated for an additional 10 min at 37°C. Samples were diluted 10-fold and drip streaked to determine colony counts.
[0193] The data show that MM12 eradicated a starting pathogen cell population of about 10E5 to about 10E7 within less than 2 minutes of exposure. Table 15 shows the results of the experiment. * indicates that the experiment was performed in triplicate.
[0194] [Table 15]
[0195] (Example 19) Evaluation of the efficacy of MM14 against antibiotic-susceptible and antibiotic-resistant Gram-positive and Gram-negative bacteria The efficacy of MM14 in killing drug-resistant and drug-susceptible bacteria was tested as described below: Mupirocin Ointment USP, 2% (Glenmark Pharmaceuticals Ltd, Mahwah, NJ), Actavis Bacitracin Zinc Ointment, 1 oz (Actavis Generics, Parsippany-Troy Hills, NJ), Vitacilina Neomycin Sulfate Ointment First Aid (Teresa Cecena DBA Genesis, San Ysidro, CA) and Equate Triple Antibiotic Ointment, 1 oz (Walmart, Bentonville, AR) were used as comparisons to MM14 in most efficacy screens. MM7, together with the above ointment, was used to inoculate against VRE ATCC 51299, MRSA ATCC BAA-44, CRE NDM-1 ATCC BAA-2146, multidrug-resistant A. baumannii ATCC BAA-1797, multidrug-resistant P. aeruginosa ATCC BAA-2114, E. coli O157:H7 ATCC 51657, S. maltophilia ATCC 13637, M. abscessus ATCC 19977, B. cepacia ATCC 10856, S. flexneri 85W 2332, S. enteriditis CDC AR0496, Streptococcus pyogenes 85W 1180, Y. pestis KIM6, Clostridium spp. ATCC 3584, N. gonorrhoeae ATCC 3591, N. gonorrhea CDC AR0214, P. acnes ATCC 6919, multidrug-resistant E. coli CDC AR0493, and S. mutans 85W2357. For the screening procedure, approximately 1 x 108 CFU / mL were plated on MHA plates.After inoculation of the bacterial lawn, 10 μL of MM14 and 10 μL spots of Mupirocin Ointment, Actavis Bacitracin Zinc Ointment, Vitacilina Neomycin Sulfate Ointment, and Equate Triple Antibiotic Ointment were added to the plates. Plates were then incubated at 37°C for 24–48 hours before being visually assessed for antimicrobial susceptibility.
[0196] As shown in Table 16, MM14 had antibacterial activity against all 17 antibiotic-susceptible and antibiotic-resistant Gram-positive and Gram-negative bacterial strains tested. MM14 was also the best and often the only effective treatment against a diverse panel of bacterial strains evaluated. For example, MM14 was the only effective treatment against VRE ATCC 25922, CRE NDM-1 ATCC BAA-2146, A. baumannii ATCC BAA-1797, and M. abscessus ATCC 19977. The prescription drug Mupirocin Ointment was the leading competitor for broad-spectrum antibacterial activity.
[0197] [Table 16]
[0198] (Example 18) Evaluation of the disinfectant efficacy of MM14 and MM18 using a time-kill kinetic assay. The disinfecting properties of MM14 and MM18 were evaluated against each of the bacterial and fungal species. All bacterial species were grown in MH broth for 12 hours at 37 °C in a rotary shaking incubator (100 rpm). Candida albicans ATCC 26555 was grown in YM for 18 hours at 37 °C in a rotary shaking incubator. 1.6 mL Eppendorf tubes were prepared with: 1) 90 μL of MH or YM; 2) 90 μL of Letheen Neutralizing Buffer (LET, also known as Blocking Buffer; 5 g / L beef extract, 0.7 g / L lecithin, 5 g / L polysorbate 80, and 5 g / L sodium chloride); 3) 90 μL of MycoDelens or MycoAmet; and 4) 90 μL of LET. 10 μL of undiluted cell suspension (1 × 10 5 ~1×10 8 CFU / mL) were added to each of the above tubes and incubated for 30 seconds, 2 minutes, 10 minutes, or 15 minutes at room temperature. After the indicated amount of time, 10 μL of cell suspension was removed from 3) and resuspended in 4) to neutralize the toxicity of MM14 and MM18. Samples were placed in CytoOne 96-well microtiter plates (USA Scientific, Orlando, FL), diluted 10-fold, and drip-streaked onto 100 mm × 15 mm Mueller-Hinton agar (MHA) plates (Simport Scientific Inc., Saint-Mathieu-de-Beloeil, QC). MHA plates were incubated for 12 hours at 37°C, and the efficacy of the disinfecting properties of MM14 and MM18 was evaluated in terms of colony forming units on the remaining viable bacterial and fungal populations.
[0199] The data shows that MM14 and MM18 are approximately 1 × 10 5 ~Approx. 1×10 7 100% of the pathogen's starting cell population was eradicated within less than 2 minutes of exposure. Table 17 shows the results of the experiment. * indicates experiments performed on MM18 in contrast to MM14. All experiments were performed in triplicate.
[0200] [Table 17]
[0201] (Example 20) Effect of MM14 on P. mirabilis The efficacy of MM14 in killing Proteus mirabilis (P. mirabilis), an oral bacterium that causes Alzheimer's disease, was tested. Briefly, P. mirabilis, 85W 1895, was grown in Mueller-Hinton (MH) broth at 37°C for 12 hours in a rotary shaking incubator. As a screening procedure, approximately 1 × 10 8 CFU / mL were plated on MHA plates. Following inoculation of the bacterial lawn, 10 μL of MM14 was added to the plates. Plates were then incubated for 18 hours at 37° C. before visually assessing antimicrobial susceptibility. As shown in Figure 92, MM14 eradicated P. mirabilis when delivered in both water and PG.
[0202] Example 21 Effect of MM14 on S. mutans MM14 was screened against Streptococcus mutans (S. mutans) 85W2357, a bacterium that causes dental caries. S. mutans was grown in Brain Heart Infusion broth at 37°C for 12 hours in a rotary shaking incubator. Approximately 1 × 10 8 CFU / mL were plated onto MHA plates. Following inoculation of the bacterial lawn, 10 μL of MM14 was added to the plates. Plates were then incubated at 37°C for 24-48 hours before visually assessing antimicrobial susceptibility. As shown in Figure 93, MM14 eradicated the growth of S. mutans.
[0203] Example 22 Effect of MM14 on P. acnes MM14 was screened against Propionibacterium acnes (P. acnes) ATCC 6919, the causative bacterium of acne. P. acnes was grown in TSB with 5% defibrinated sheep blood in an anaerobic chamber in the presence of a gas mixture consisting of 80% N2, 10% CO2, and 10% H2 in a rotary shaking incubator (100 rpm) at 37 °C for 11 days. For the screening procedure, approximately 1 × 10 8 CFU / mL were plated onto MHA plates. Following inoculation of the bacterial lawn, 10 μL of MM14 was added to the plates. Plates were then incubated for an additional 11 days at 37° C. in an anaerobic chamber before visually assessing antimicrobial susceptibility. As shown in Figure 94, MM14 eradicated the growth of P. acnes.
[0204] Example 23 Effect of MM14 against Salmonella enteriditis, Shigella flexneri, Streptococcus pyogenes, Burkholderia cepacia, Clostridium species, and Yersinia pestis Burkholderia cepacia ATCC 10856, Streptococcus pyogenes 85W, and Yersinia pestis (KIM6) were grown in Mueller-Hinton broth at 37°C for 12 hours in a rotary shaking incubator (100 rpm). Shigella flexneri 85W 2332 and Salmonella enteriditis CDC AR0496 were grown in Brain Heart Infusion broth (BHI) at 37°C for 12 hours in a rotary shaking incubator. Clostridium sp. ATCC 3584 was grown in Trypticase Soy Broth (BD™ Tryptic Soy Broth (TSB) BD, Franklin Lakes, NJ) in an anaerobic chamber in the presence of a gas mixture of 80% N2, 10% CO2, and 10% H2 (BD BBL™ CO2 generator, Franklin Lakes, NJ) at 37°C for 10 days. The efficacy of MM14 in killing the above-mentioned pathogens was tested and compared to various commercial products. Mupirocin Ointment USP, 2%, Actavis Bacitracin Zinc Ointment, Vitacilina Neomycin Sulfate ointment First Aid, Equate Triple Antibiotic Ointment, and Chlorhexidine Gluconate 0.12% were used as comparisons to MM14 in most efficacy screens. MM14 together with the above ointment was screened against Burkholderia cepacia (B. cepacia) ATCC 10856, Shigella flexneri (S. flexneri) 85W 2332, Salmonella enteriditis (S. enteriditis) CDC AR0496, Streptococcus pyogenes (S. pyogenes) 85W 1180, Yersinia pestis (Y. pestis) KIM6, and Clostridium species ATCC 3584. For the screening procedure, approximately 1 × 10 8CFU / mL were plated onto MHA plates. Following inoculation of the bacterial lawn, 10 μL of MM14 and 10 μL spots of Mupirocin Ointment, Actavis Bacitracin Zinc Ointment, Vitacilina Neomycin Sulfate Ointment, Chlorhexidine Gluconate 0.12%, and Equate Triple Antibiotic Ointment were added to the MHA plates. Plates were then incubated at 37°C for 24-48 hours (all pathogens except Clostridium spp., which were incubated for 20 days) and then visually assessed for antimicrobial susceptibility. The results, shown in Figure 95, indicate that MM14 was able to eradicate each of the pathogens tested.
[0205] Example 24 Bactericidal efficacy of MM14 and MM18 against X. campestris 19155 and Clavibacter sp. ATCC 43179 The bactericidal efficacy of MM14 and MM18 against two pathogens associated with crop failure, Xanthomonas campestris (X. campestris) ATCC 19155 and Clavibacter spp., were evaluated. X. campestris ATCC 19155 and Clavibacter spp. ATCC 43179 were grown in BHI broth at 26 °C for 12 h in a rotary shaking incubator (100 rpm). To screen MM14 and MM18 against the pathogens, approximately 1 × 10 8 CFU / mL were plated onto BHI plates. Following inoculation of the bacterial lawn, 10 μL of MM14 and 10 μL of MM18 were added to the BHI plates. The plates were then incubated for 18 hours at 26° C. before visually assessing antimicrobial susceptibility. The results are shown in FIG. 96 and show that both MM14 and MM18 eradicated X. campestris ATCC 19155 and Clavibacter spp. ATCC 43179.
[0206] (Example 25) Quantification of the bactericidal efficacy of MM14 against X. campestris 19155 and Clavibacter sp. ATCC 43179 The disinfecting properties of MM14 were quantified against each of X. campestris 19155 and Clavibacter sp. ATCC 43179. Each bacterial species was grown in BHI broth for 12 hours at 26°C in a rotary shaking incubator (100 rpm). 1.6 mL Eppendorf tubes were prepared with: 1) 90 μL of either BHI; 2) 90 μL of Letheen Neutralizing Buffer (LET Blocking Buffer; 5 g / L beef extract, 0.7 g / L lecithin, 5 g / L polysorbate 80, and 5 g / L sodium chloride); 3) 90 μL of MM14; and 4) 90 μL of LET. 10 μL of undiluted cell suspension (1 × 10 8 CFU / mL) was added to each of the above tubes and incubated for 30 seconds or 2 minutes at room temperature. After the indicated amount of time, 10 μL of cell suspension was removed from 3) and resuspended in 4) to neutralize the toxicity of MM14. Samples were placed in CytoOne 96-well microtiter plates, diluted 10-fold, and drip streaked onto 100 mm×15 mm BHI plates. The BHI plates were incubated for 12 hours at 26° C., and the efficacy of the disinfecting properties of MM14 was evaluated as colony forming units on the remaining viable bacterial and fungal populations. As shown in FIG. 97, MM14 caused complete killing of both X. campestris and Clavibacter species after 30 seconds of treatment.
[0207] (Example 26) Effect of MM14 and MM18 on Porphyromonas gingivalis (P. gingivalis) P. gingivalis is grown anaerobically (80% N, 10% CO, 10% H) for 48 hours at 37°C in Trypticase Soy Broth (TSB) enriched with 0.25% yeast extract, 2.5 μg / ml hemin, 5.0 μg / ml menadione, and 0.01% dithiothreitol (DTT). Approximately 1 × 10 7Inoculate 100 cells / mL. After inoculation of the bacterial lawn, 10 μL of MM14, 10 μL of MM18, 10 μL of Chlorhexidine Gluconate 0.12%, 10 μL of Listerine Naturals Antiseptic Mouthwash, and 10 μL of Crest Pro-Health Multiprotection Rinse are then added to separate areas of the plate. Plates are then incubated at 37°C in anaerobic conditions for 48 hours before visually assessing antimicrobial susceptibility.
[0208] Example 27 Testing the efficacy of MM18 powder against A. baumannii ATCC 1997 To obtain MM18 in powder form, a liquid preparation of MM18 was placed in a sterile T75 tissue culture flask with a vented cap and left until 100 mL of liquid dried to a glass-like consistency at the bottom of the flask. A mortar and pestle was then used to convert the dried MM18 into a powder. MHA plates were then inoculated with a lawn of A. baumannii ATCC BAA-1797. To test the efficacy of MM18 powder against A. baumannii, MM18 poser was sprinkled on the surface of the inoculated plate. After 18 hours of incubation at 37°C, the plates were visually assessed for antimicrobial susceptibility. As can be seen in Figure 98, MM18 powder eradicated A. baumannii in the area where it was added.
[0209] (Example 28) Testing the antiviral efficacy of MM14 and MM15 To determine the efficacy of MM14 and MM15 as antiviral drugs, human cervical adenocarcinoma (HeLa) cells are grown in T25 tissue culture flasks in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS) in a 37°C incubator with 5% CO2 until confluent. To prepare stock virus cultures (e.g., vaccinia virus), HeLa cells are split and plated in 6-well plates, allowed to attach for 12 hours in a 37°C incubator with 5% CO2, and infected with 0.1 plaque-forming units (PFU) per cell, delivered in a minimal volume to cover the surface of the HeLa cells. Samples are incubated for 30 minutes at 37°C in 5% CO2. After incubation, the inoculum is aspirated and replaced with fresh DMEM and FBS before being reincubated for 48 hours at 37°C in 5% CO2. After 48 hours of incubation, the supernatant is discarded and the infected HeLa cells are resuspended in 1 mM Tris pH 9.0. Three freeze-thaw cycles are performed and the samples are purified by passing them through a sucrose cushion. For purification through a sucrose cushion, after the freeze-thaw cycles the samples are mixed by vortexing and spun in a centrifuge at 1.2K for 10 minutes. The resulting supernatant is collected and saved, while the pellet is resuspended in 15 mL of 1 mM Tris pH 9.0, mixed by vortexing and spun in a centrifuge at 1.2K for 10 minutes. The resulting supernatant is also collected. 15 mL of 36% w / v sucrose in 1 mM Tris pH 9.0 is added to an ultracentrifuge tube and 20 mL of the virus sample is added slowly, taking great care not to mix the sample. Finally, the virus titer of the stock is determined. The samples are then spun in an ultracentrifuge for 1 hour at 20K and 4°C. After ultracentrifugation, the supernatant is aspirated and the pellet is resuspended in 1 mL of 1 mM Tris pH 9.0.
[0210] After determining the viral titer, a plaque assay is performed as follows: 10 μL of virus stock is mixed with 10 μL of sterile 0.25 mg / ml trypsin. The mixture is incubated in a 37°C water bath and mixed by vortexing every 10 min during incubation. Immediately after incubation, dilutions ranging from 10-2 to 10-10 are prepared in DMEM plus FBS. Media is aspirated from the 6-well plate and 200 μL of virus dilution is added to 1 mL of DMEM plus FBS. This virus mixture is dispensed into each well of the 6-well plate. Sample treatments include wells treated with 50%, 10%, 5%, 1%, and 0.5% v / v MM14 and / or MM15 along with a negative control. Plates are incubated at 37°C for 30 min in 5% CO2. After incubation, the inoculum is aspirated and replaced with 3 mL of DMEM containing 2% FBS. The plates are then incubated for 48 hours at 37° C. in 5% CO2. To enumerate PFU / cells, the medium is aspirated from each well after 48 hours of incubation. 2 mL of crystal violet (0.1% crystal violet in 20% ethanol) is added and the plates are incubated for 10 minutes at room temperature. The dye is then aspirated, the wells are washed with water, and the number of plaques is counted.
[0211] (Example 29) Anti-infective properties of MM14 in combination with other formulations The efficacy of MM14 in combination with other formulations to kill MRSA BAA-44, P. aeruginosa ATCC 2114, A. baumannii ATCC 1797, and C. albicans ATCC 26555 was tested as described below. Organisms were grown in Mueller-Hinton (MH) broth at 37° C. for 12 hours in a rotary shaking incubator. Approximately 1×10 8CFU / mL were plated onto MHA plates. Following inoculation of the bacterial lawn, 10 μL of MM14, Feminease® Feminine Moisturizer, Pretz Nasal Spray, Mouth Kote Dry Mouth Spray, Feminease® Feminine Moisturizer + MM14, Pretz Nasal Spray + MM14, and Mouth Kote Dry Mouth Spray + MM14 were added to the plates. Plates were then incubated for 18 hours at 37° C. before visually assessing antimicrobial susceptibility. As can be seen in FIG. 99, the addition of MM14 to existing formulations conferred anti-infective properties to those formulations.
[0212] (Example 30) Evaluation of seed germination after treatment with MM14 and MM18 To evaluate the potential of MM14 and MM18 to protect crops from infection, the effect of MM14 and MM18 on seed germination was evaluated. Sweet snap pea and corn seeds were divided into six treatment groups as follows: 1) no treatment, 2) washed with sterile water, 3) washed with MM14, 4) washed with MM18, 5) washed with MM14 and then washed with water, and 6) washed with MM18 and then washed with water. Seeds were treated for 10 minutes and then planted in soil. Seeds were watered and placed in sunlight for 2 weeks before evaluating germination efficiency. As can be seen in Figure 100, there was no significant difference in germination efficiency between the treatment groups.
[0213] Embodiment The following non-limiting embodiments provide specific examples of the present invention, but do not limit the scope of the invention. Embodiment 1. A pharmaceutical composition comprising, in a unit dosage form, a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent which is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. Embodiment 2. The pharmaceutical composition of embodiment 1, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. Embodiment 3. The pharmaceutical composition of embodiment 1, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. Embodiment 4. The pharmaceutical composition of any one of embodiments 1 to 3, wherein the cationic surfactant is present in a concentration of about 1 mM to about 500 mM. Embodiment 5. The pharmaceutical composition of any one of embodiments 1 to 4, wherein the cationic surfactant is present in a concentration of about 1 mM. Embodiment 6. The pharmaceutical composition of any one of embodiments 1 to 4, wherein the cationic surfactant is present in a concentration of about 400 mM. Embodiment 7. The pharmaceutical composition of any one of embodiments 1 to 4, wherein the cationic surfactant is present in a concentration of about 500 mM. Embodiment 8. The pharmaceutical composition of any one of embodiments 1 to 7, wherein the chelating agent is present in a concentration of about 10 mM to about 500 mM. Embodiment 9. The pharmaceutical composition of any one of embodiments 1 to 8, wherein the chelating agent is present in a concentration of about 10 mM. Embodiment 10. The pharmaceutical composition of any one of embodiments 1 to 8, wherein the chelating agent is present in a concentration of about 250 mM. Embodiment 11. The pharmaceutical composition of any one of embodiments 1 to 8, wherein the chelating agent is present in a concentration of about 300 mM. Embodiment 12. The pharmaceutical composition of any one of embodiments 1 to 8, wherein the chelating agent is present in a concentration of about 500 mM. Embodiment 13. A pharmaceutical composition according to any one of embodiments 1 to 12, wherein the solvent is an organic solvent. Embodiment 14. A pharmaceutical composition according to any one of embodiments 1 to 12, wherein the solvent comprises propylene glycol. Embodiment 15. A pharmaceutical composition according to any one of embodiments 1 to 12, wherein the solvent comprises petrolatum. Embodiment 16. The pharmaceutical composition of any one of embodiments 1 to 12, wherein the solvent comprises an organic solvent and an aqueous solvent. Embodiment 17. The pharmaceutical composition of embodiment 16, wherein the organic solvent is present in an amount of about 25%. Embodiment 18. The pharmaceutical composition of embodiment 16, wherein the organic solvent is present in an amount of about 50%. Embodiment 19. A pharmaceutical composition according to any one of embodiments 16, wherein the organic solvent is propylene glycol and the aqueous solvent is water. Embodiment 20. The pharmaceutical composition of any one of embodiments 16 to 18, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water. Embodiment 21. The pharmaceutical composition of any one of embodiments 16 to 18, wherein the organic solvent is ethanol and the aqueous solvent is water. Embodiment 22. The pharmaceutical composition of any one of embodiments 16 to 18, wherein the organic solvent is glycerol and the aqueous solvent is water. Embodiment 23. A pharmaceutical composition according to any one of embodiments 1 to 22, wherein the pharmaceutical composition further comprises an antibiotic. Embodiment 24. The pharmaceutical composition of embodiment 23, wherein the antibiotic is polymyxin B.
[0214] Embodiment 25. A method of killing a microorganism, the method comprising administering to the microorganism a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising, in a unit dosage form, a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. Embodiment 26 The method of embodiment 25, wherein the microorganism is a bacterium. Embodiment 27 The method of embodiment 25, wherein the microorganism is a fungus. Embodiment 28 The method of embodiment 27, wherein the fungus is a mold. Embodiment 29 The method of embodiment 25, wherein the microorganism is a yeast. Embodiment 30 The method of embodiment 25, wherein the microorganism is a virus. Embodiment 31. The method of any one of embodiments 25-30, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. Embodiment 32. The method of any one of embodiments 25-30, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. Embodiment 33. The method of any one of embodiments 25 to 32, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM. Embodiment 34. The method of any one of embodiments 25 to 33, wherein the cationic surfactant is present at a concentration of about 1 mM. Embodiment 35. The method of any one of embodiments 25 to 33, wherein the cationic surfactant is present at a concentration of about 400 mM. Embodiment 36 The method of any one of embodiments 25 to 33, wherein the cationic surfactant is present at a concentration of about 500 mM. Embodiment 37. The method of any one of embodiments 25 to 36, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM. Embodiment 38. The method of any one of embodiments 25 to 37, wherein the chelating agent is present at a concentration of about 10 mM. Embodiment 39. The method of any one of embodiments 25 to 37, wherein the chelating agent is present at a concentration of about 250 mM. Embodiment 40. The method of any one of embodiments 25 to 37, wherein the chelating agent is present at a concentration of about 300 mM. Embodiment 41 The method of any one of embodiments 25 to 37, wherein the chelating agent is present at a concentration of about 500 mM. Embodiment 42. The method of any one of embodiments 25 to 41, wherein the solvent is an organic solvent. Embodiment 43. The method of any one of embodiments 25 to 41, wherein the solvent comprises propylene glycol. Embodiment 44. The method of any one of embodiments 25 to 41, wherein the solvent comprises petrolatum. Embodiment 45. The method of any one of embodiments 25-41, wherein the solvent comprises an organic solvent and an aqueous solvent. Embodiment 46 The method of embodiment 45, wherein the organic solvent is present in an amount of about 25%. Embodiment 47. The method of embodiment 45, wherein the organic solvent is present in an amount of about 50%. Embodiment 48. The method of any one of embodiments 45 to 47, wherein the organic solvent is propylene glycol and the aqueous solvent is water. Embodiment 49. The method of any one of embodiments 45 to 47, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water. Embodiment 50. The method of any one of embodiments 45-47, wherein the organic solvent is ethanol and the aqueous solvent is water. Embodiment 51. The method of any one of embodiments 45 to 47, wherein the organic solvent is glycerol and the aqueous solvent is water. Embodiment 52. The method of any one of embodiments 25 to 51, wherein the pharmaceutical composition further comprises an antibiotic. Embodiment 53 The method of embodiment 52, wherein the antibiotic is polymyxin B. Embodiment 54. The method of any one of embodiments 25 to 53, wherein the microorganism is on a plant.
[0215] Embodiment 55. A method for treating an infectious disease, the method comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. Embodiment 56 The method of embodiment 55, wherein the microorganism is a bacterium. Embodiment 57. The method of embodiment 55, wherein the microorganism is a fungus. Embodiment 58. The method of embodiment 57, wherein the fungus is a mold. Embodiment 59. The method of embodiment 55, wherein the microorganism is a yeast. Embodiment 60. The method of embodiment 55, wherein the microorganism is a virus. Embodiment 61. The method of any one of embodiments 55-60, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. Embodiment 62. The method of any one of embodiments 55-60, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. Embodiment 63. The method of any one of embodiments 55 to 62, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM. Embodiment 64. The method of any one of embodiments 55 to 63, wherein the cationic surfactant is present at a concentration of about 1 mM. Embodiment 65. The method of any one of embodiments 55 to 63, wherein the cationic surfactant is present at a concentration of about 400 mM. Embodiment 66. The method of any one of embodiments 55 to 63, wherein the cationic surfactant is present at a concentration of about 500 mM. Embodiment 67. The method of any one of embodiments 55 to 66, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM. Embodiment 68. The method of any one of embodiments 55 to 67, wherein the chelating agent is present at a concentration of about 10 mM. Embodiment 69. The method of any one of embodiments 55 to 67, wherein the chelating agent is present at a concentration of about 250 mM. Embodiment 70. The method of any one of embodiments 55 to 67, wherein the chelating agent is present at a concentration of about 300 mM. Embodiment 71. The method of any one of embodiments 55 to 67, wherein the chelating agent is present at a concentration of about 500 mM. Embodiment 72. The method of any one of embodiments 55 to 71, wherein the solvent is an organic solvent. Embodiment 73. The method of any one of embodiments 55-71, wherein the solvent comprises propylene glycol. Embodiment 74. The method of any one of embodiments 55-71, wherein the solvent comprises petrolatum. Embodiment 75. The method of any one of embodiments 55-71, wherein the solvent comprises an organic solvent and an aqueous solvent. Embodiment 76 The method of embodiment 75, wherein the organic solvent is present in an amount of about 25%. Embodiment 77. The method of embodiment 75, wherein the organic solvent is present in an amount of about 50%. Embodiment 78. The method of any one of embodiments 75 to 77, wherein the organic solvent is propylene glycol and the aqueous solvent is water. Embodiment 79. The method of any one of embodiments 75 to 77, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water. Embodiment 80. The method of any one of embodiments 75-77, wherein the organic solvent is ethanol and the aqueous solvent is water. Embodiment 81. The method of any one of embodiments 75-77, wherein the organic solvent is glycerol and the aqueous solvent is water. Embodiment 82. The method of any one of embodiments 55 to 81, wherein the pharmaceutical composition further comprises an antibiotic. Embodiment 83 The method of embodiment 82, wherein the antibiotic is polymyxin B.
[0216] Embodiment 84. A method for disinfecting a surface, the method comprising administering an effective amount of a pharmaceutical composition to a surface in need thereof, the pharmaceutical composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. Embodiment 85. The method of embodiment 84, wherein the microorganism is a bacterium. Embodiment 86 The method of embodiment 84, wherein the microorganism is a fungus. Embodiment 87. The method of embodiment 86, wherein the fungus is a mold. Embodiment 88. The method of embodiment 84, wherein the microorganism is a yeast. Embodiment 89. The method of embodiment 84, wherein the microorganism is a virus. Embodiment 90. The method of any one of embodiments 84-89, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. Embodiment 91. The method of any one of embodiments 84-89, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. Embodiment 92. The method of any one of embodiments 84 to 91, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM. Embodiment 93. The method of any one of embodiments 84 to 92, wherein the cationic surfactant is present at a concentration of about 1 mM. Embodiment 94. The method of any one of embodiments 84 to 92, wherein the cationic surfactant is present at a concentration of about 400 mM. Embodiment 95. The method of any one of embodiments 84 to 92, wherein the cationic surfactant is present at a concentration of about 500 mM. Embodiment 96. The method of any one of embodiments 84 to 95, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM. Embodiment 97. The method of any one of embodiments 84 to 96, wherein the chelating agent is present at a concentration of about 10 mM. Embodiment 98. The method of any one of embodiments 84 to 96, wherein the chelating agent is present at a concentration of about 250 mM. Embodiment 99. The method of any one of embodiments 84 to 96, wherein the chelating agent is present at a concentration of about 300 mM. Embodiment 100. The method of any one of embodiments 84-96, wherein the chelating agent is present at a concentration of about 500 mM. Embodiment 101. The method of any one of embodiments 84 to 100, wherein the solvent is an organic solvent. Embodiment 102. The method of any one of embodiments 84 to 100, wherein the solvent comprises propylene glycol. Embodiment 103. The method of any one of embodiments 84 to 100, wherein the solvent comprises petrolatum. Embodiment 104. The method of any one of embodiments 84 to 100, wherein the solvent comprises an organic solvent and an aqueous solvent. Embodiment 105. The method of embodiment 104, wherein the organic solvent is present in an amount of about 25%. Embodiment 106 The method of embodiment 104, wherein the organic solvent is present in an amount of about 50%. Embodiment 107. The method of any one of embodiments 104-106, wherein the organic solvent is propylene glycol and the aqueous solvent is water. Embodiment 108. The method of any one of embodiments 104 to 106, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water. Embodiment 109. The method of any one of embodiments 104 to 106, wherein the organic solvent is ethanol and the aqueous solvent is water. Embodiment 110. The method of any one of embodiments 104 to 106, wherein the organic solvent is glycerol and the aqueous solvent is water. Embodiment 111. The method according to any one of embodiments 84 to 110, wherein the pharmaceutical composition further comprises an antibiotic. Embodiment 112. The method of embodiment 111, wherein the antibiotic is polymyxin B.
[0217] Embodiment 113. A method for sterilizing produce, the method comprising contacting the produce with an effective amount of a composition, the composition comprising, in a unit dosage form: a) a cationic surfactant that is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma-ceutically acceptable salt thereof; and c) a solvent. Embodiment 114. The method of embodiment 113, wherein the agricultural product is a seed. Embodiment 115. The method of embodiment 113, wherein the agricultural product is a plant. Embodiment 116. The method of embodiment 113, wherein the agricultural product is a food-producing plant. Embodiment 117. The method of any one of embodiments 113 to 116, wherein the produce is infected with bacteria. Embodiment 118. The method of any one of embodiments 113 to 116, wherein the produce is infected with a fungus. Embodiment 119. The method of embodiment 118, wherein the fungus is a mold. Embodiment 120. The method of any one of embodiments 113 to 116, wherein the produce is infected with yeast. Embodiment 121. The method of any one of embodiments 113 to 116, wherein the produce is infected with a virus. Embodiment 122. The method of any one of embodiments 113 to 121, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. Embodiment 123. The method of any one of embodiments 113 to 121, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. Embodiment 124. The method of any one of embodiments 113 to 123, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM. Embodiment 125. The method of any one of embodiments 113 to 124, wherein the cationic surfactant is present at a concentration of about 1 mM. Embodiment 126. The method of any one of embodiments 113 to 124, wherein the cationic surfactant is present at a concentration of about 400 mM. Embodiment 127. The method of any one of embodiments 113 to 124, wherein the cationic surfactant is present at a concentration of about 500 mM. Embodiment 128. The method of any one of embodiments 113 to 127, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM.
[0218] Embodiment 129. The method of any one of embodiments 113 to 128, wherein the chelating agent is present at a concentration of about 10 mM. Embodiment 130. The method of any one of embodiments 113 to 128, wherein the chelating agent is present at a concentration of about 250 mM. Embodiment 131. The method of any one of embodiments 113 to 128, wherein the chelating agent is present at a concentration of about 300 mM. Embodiment 132. The method of any one of embodiments 113 to 128, wherein the chelating agent is present at a concentration of about 500 mM. Embodiment 133. The method of any one of embodiments 113 to 132, wherein the solvent is an organic solvent. Embodiment 134. The method of any one of embodiments 113 to 132, wherein the solvent comprises propylene glycol. Embodiment 135. The method of any one of embodiments 113 to 132, wherein the solvent comprises petrolatum. Embodiment 136. The method of any one of embodiments 113 to 132, wherein the solvent comprises an organic solvent and an aqueous solvent. Embodiment 137. The method of embodiment 136, wherein the organic solvent is present in an amount of about 25%. Embodiment 138. The method of embodiment 136, wherein the organic solvent is present in an amount of about 50%. Embodiment 139. The method of any one of embodiments 136 to 138, wherein the organic solvent is propylene glycol and the aqueous solvent is water. Embodiment 140. The method of any one of embodiments 136 to 138, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water. Embodiment 141. The method of any one of embodiments 136-138, wherein the organic solvent is ethanol and the aqueous solvent is water. Embodiment 142. The method of any one of embodiments 136 to 138, wherein the organic solvent is glycerol and the aqueous solvent is water. Embodiment 143. The method according to any one of embodiments 113 to 142, wherein the pharmaceutical composition further comprises an antibiotic. Embodiment 144. The method of embodiment 143, wherein the antibiotic is polymyxin B. Yet another aspect of the present invention may be as follows. [1] In the unit dosage form, a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) Solvent 23. A pharmaceutical composition comprising: [2] The pharmaceutical composition according to [1] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide. [3] The pharmaceutical composition according to [1] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride. [4] The pharmaceutical composition according to [1] above, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM. [5] The pharmaceutical composition according to [1] above, wherein the cationic surfactant is present at a concentration of about 1 mM. [6] The pharmaceutical composition according to [1] above, wherein the cationic surfactant is present at a concentration of about 400 mM. [7] The pharmaceutical composition according to [1] above, wherein the cationic surfactant is present at a concentration of about 500 mM. [8] The pharmaceutical composition according to [1] above, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM. [9] The pharmaceutical composition according to [1], wherein the chelating agent is present at a concentration of about 10 mM.
[10] The pharmaceutical composition according to [1], wherein the chelating agent is present at a concentration of about 250 mM.
[11] The pharmaceutical composition according to [1], wherein the chelating agent is present at a concentration of about 300 mM.
[12] The pharmaceutical composition according to [1], wherein the chelating agent is present at a concentration of about 500 mM.
[13] The pharmaceutical composition according to [1] above, wherein the solvent is an organic solvent.
[14] The pharmaceutical composition according to [1] above, wherein the solvent comprises propylene glycol.
[15] The pharmaceutical composition described in [1] above, wherein the solvent comprises petrolatum.
[16] The pharmaceutical composition according to [1] above, wherein the solvent comprises an organic solvent and an aqueous solvent.
[17] The pharmaceutical composition according to
[16] , wherein the organic solvent is present in an amount of about 25%.
[18] The pharmaceutical composition according to
[16] , wherein the organic solvent is present in an amount of about 50%.
[19] The pharmaceutical composition according to
[16] above, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
[20] The pharmaceutical composition according to
[16] above, wherein the organic solvent is dimethylsulfoxide and the aqueous solvent is water.
[21] The pharmaceutical composition according to
[16] above, wherein the organic solvent is ethanol and the aqueous solvent is water.
[22] The pharmaceutical composition according to
[16] above, wherein the organic solvent is glycerol and the aqueous solvent is water.
[23] The pharmaceutical composition according to [1] above, further comprising an antibiotic.
[24] The pharmaceutical composition according to
[23] above, wherein the antibiotic is polymyxin B.
[25] A method for killing a microorganism, comprising administering to the microorganism a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form comprising: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) Solvent A method comprising:
[26] The method according to
[25] above, wherein the microorganism is a bacterium.
[27] The method according to
[25] above, wherein the microorganism is a fungus.
[28] The method according to
[27] above, wherein the fungus is a mold.
[29] The method according to
[25] above, wherein the microorganism is yeast.
[30] The method according to
[25] above, wherein the microorganism is a virus.
[31] The method according to
[25] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
[32] The method according to
[25] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
[33] The method according to
[25] above, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
[34] The method according to
[25] above, wherein the cationic surfactant is present at a concentration of about 1 mM.
[35] The method according to
[25] above, wherein the cationic surfactant is present at a concentration of about 400 mM.
[36] The method according to
[25] above, wherein the cationic surfactant is present at a concentration of about 500 mM.
[37] The method according to
[25] above, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM.
[38] The method according to
[25] above, wherein the chelating agent is present at a concentration of about 10 mM.
[39] The method according to
[25] above, wherein the chelating agent is present at a concentration of about 250 mM.
[40] The method of claim 25, wherein the chelating agent is present at a concentration of about 300 mM.
[41] The method according to
[25] above, wherein the chelating agent is present at a concentration of about 500 mM.
[42] The method according to
[25] above, wherein the solvent is an organic solvent.
[43] The method according to
[25] above, wherein the solvent comprises propylene glycol.
[44] The method according to
[25] above, wherein the solvent comprises petrolatum.
[45] The method according to
[25] above, wherein the solvent comprises an organic solvent and an aqueous solvent.
[46] The method according to
[45] above, wherein the organic solvent is present in an amount of about 25%.
[47] The method according to
[45] above, wherein the organic solvent is present in an amount of about 50%.
[48] The method according to
[45] above, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
[49] The method according to
[45] above, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
[50] The method according to
[45] above, wherein the organic solvent is ethanol and the aqueous solvent is water.
[51] The method according to
[45] above, wherein the organic solvent is glycerol and the aqueous solvent is water.
[52] The method according to
[25] , wherein the pharmaceutical composition further comprises an antibiotic.
[53] The method according to
[52] above, wherein the antibiotic is polymyxin B.
[54] The method according to
[25] above, wherein the microorganism is on a plant.
[55] A method for treating an infectious disease, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form comprising: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) Solvent A method comprising:
[56] The method according to
[55] above, wherein the infectious disease is caused by a bacterium.
[57] The method according to
[55] above, wherein the infectious disease is caused by a fungus.
[58] The method according to
[57] above, wherein the fungus is a mold.
[59] The method according to
[55] above, wherein the infectious disease is caused by yeast.
[60] The method according to
[55] above, wherein the infectious disease is caused by a virus.
[61] The method according to
[55] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
[62] The method according to
[55] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
[63] The method according to
[55] above, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
[64] The method according to
[55] above, wherein the cationic surfactant is present at a concentration of about 1 mM.
[65] The method according to
[55] , wherein the cationic surfactant is present at a concentration of about 400 mM.
[66] The method according to
[55] above, wherein the cationic surfactant is present at a concentration of about 500 mM.
[67] The method according to
[55] above, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM.
[68] The method according to
[55] , wherein the chelating agent is present at a concentration of about 10 mM.
[69] The method according to
[55] , wherein the chelating agent is present at a concentration of about 250 mM.
[70] The method according to
[55] , wherein the chelating agent is present at a concentration of about 300 mM.
[71] The method according to
[55] , wherein the chelating agent is present at a concentration of about 500 mM.
[72] The method according to
[55] above, wherein the solvent is an organic solvent.
[73] The method according to
[55] above, wherein the solvent comprises propylene glycol.
[74] The method according to
[55] above, wherein the solvent comprises petrolatum.
[75] The method according to
[55] above, wherein the solvent comprises an organic solvent and an aqueous solvent. 76. The method according to claim 75, wherein the organic solvent is present in an amount of about 25%.
[77] The method according to
[75] , wherein the organic solvent is present in an amount of about 50%.
[78] The method according to
[75] above, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
[79] The method according to
[75] above, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
[80] The method according to
[75] above, wherein the organic solvent is ethanol and the aqueous solvent is water.
[81] The method according to
[75] above, wherein the organic solvent is glycerol and the aqueous solvent is water.
[82] The method according to
[55] , wherein the pharmaceutical composition further comprises an antibiotic.
[83] The method according to
[82] above, wherein the antibiotic is polymyxin B.
[84] A method for disinfecting a surface, comprising administering an effective amount of a pharmaceutical composition to a surface in need thereof, the pharmaceutical composition being in a unit dosage form comprising: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) Solvent A method comprising:
[85] The method according to
[84] , wherein the surface is infected with bacteria.
[86] The method according to
[84] above, wherein the surface is infected with a fungus.
[87] The method according to
[86] above, wherein the fungus is a mold.
[88] The method according to
[84] above, wherein the surface is infected with yeast.
[89] The method according to
[84] , wherein the surface is infected with a virus.
[90] The method according to
[84] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
[91] The method according to
[84] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
[92] The method according to
[84] above, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
[93] The method according to
[84] , wherein the cationic surfactant is present at a concentration of about 1 mM.
[94] The method according to
[84] , wherein the cationic surfactant is present at a concentration of about 400 mM.
[95] The method according to
[84] , wherein the cationic surfactant is present at a concentration of about 500 mM.
[96] The method according to
[84] above, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM.
[97] The method according to
[84] , wherein the chelating agent is present at a concentration of about 10 mM.
[98] The method according to
[84] , wherein the chelating agent is present at a concentration of about 250 mM.
[99] The method according to
[84] , wherein the chelating agent is present at a concentration of about 300 mM.
[100] The method according to
[84] , wherein the chelating agent is present at a concentration of about 500 mM.
[101] The method according to
[84] above, wherein the solvent is an organic solvent.
[102] The method according to
[84] above, wherein the solvent comprises propylene glycol.
[103] The method according to
[84] , wherein the solvent comprises petrolatum.
[104] The method according to
[84] above, wherein the solvent comprises an organic solvent and an aqueous solvent.
[105] The method according to
[104] , wherein the organic solvent is present in an amount of about 25%.
[106] The method according to
[104] , wherein the organic solvent is present in an amount of about 50%.
[107] The method according to
[104] above, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
[108] The method according to
[104] above, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
[109] The method according to
[104] above, wherein the organic solvent is ethanol and the aqueous solvent is water.
[110] The method according to
[104] above, wherein the organic solvent is glycerol and the aqueous solvent is water.
[111] The method according to
[84] , wherein the pharmaceutical composition further comprises an antibiotic.
[112] The method according to
[111] above, wherein the antibiotic is polymyxin B.
[113] A method for sterilizing produce, comprising contacting the produce with an effective amount of a composition, the composition being in a unit dosage form and comprising: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent that is diethylenetriaminepentaacetic acid (DTPA) or a pharma- ceutically acceptable salt thereof; and c) Solvent A method comprising:
[114] The method according to
[113] above, wherein the agricultural product is a seed.
[115] The method according to
[113] above, wherein the agricultural product is a plant.
[116] The method according to
[113] above, wherein the agricultural product is a plant that produces food.
[117] The method according to
[113] above, wherein the agricultural produce is infected with bacteria.
[118] The method according to
[113] above, wherein the agricultural produce is infected with a fungus.
[119] The method according to
[118] above, wherein the fungus is a mold.
[120] The method according to
[113] above, wherein the agricultural produce is infected with yeast.
[121] The method according to
[113] above, wherein the agricultural produce is infected with a virus.
[122] The method according to
[113] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
[123] The method according to
[113] above, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
[124] The method according to
[113] above, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
[125] The method according to
[113] , wherein the cationic surfactant is present at a concentration of about 1 mM.
[126] The method according to
[113] above, wherein the cationic surfactant is present at a concentration of about 400 mM.
[127] The method according to
[113] above, wherein the cationic surfactant is present at a concentration of about 500 mM.
[128] The method according to
[113] above, wherein the chelating agent is present at a concentration of about 10 mM to about 500 mM.
[129] The method according to
[113] , wherein the chelating agent is present at a concentration of about 10 mM.
[130] The method according to
[113] , wherein the chelating agent is present at a concentration of about 250 mM.
[131] The method according to
[113] , wherein the chelating agent is present at a concentration of about 300 mM.
[132] The method according to
[113] , wherein the chelating agent is present at a concentration of about 500 mM.
[133] The method according to
[113] above, wherein the solvent is an organic solvent.
[134] The method according to
[113] above, wherein the solvent comprises propylene glycol.
[135] The method according to
[113] above, wherein the solvent comprises petrolatum.
[136] The method according to
[113] above, wherein the solvent comprises an organic solvent and an aqueous solvent.
[137] The method according to
[136] , wherein the organic solvent is present in an amount of about 25%.
[138] The method according to
[136] , wherein the organic solvent is present in an amount of about 50%.
[139] The method according to
[136] above, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
[140] The method according to
[136] above, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
[141] The method according to
[136] above, wherein the organic solvent is ethanol and the aqueous solvent is water.
[142] The method according to
[136] above, wherein the organic solvent is glycerol and the aqueous solvent is water.
[143] The method according to
[113] , wherein the pharmaceutical composition further comprises an antibiotic.
[144] The method according to
[143] above, wherein the antibiotic is polymyxin B.
Claims
1. Within the unit dosage form: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent which is diethylenetriaminepentaacetic acid (DTPA); and c) Solvent wherein said pharmaceutical composition does not include chlorhexidine.
2. 2. The pharmaceutical composition of claim 1, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
3. 2. The pharmaceutical composition of claim 1, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
4. 10. The pharmaceutical composition of claim 1, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
5. 10. The pharmaceutical composition of claim 1, wherein the solvent comprises ethanol.
6. 10. The pharmaceutical composition of claim 1, wherein the solvent comprises an organic solvent and an aqueous solvent.
7. 7. The pharmaceutical composition of claim 6, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
8. 7. The pharmaceutical composition of claim 6, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
9. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises an antibiotic.
10. 10. The pharmaceutical composition of claim 9, wherein the antibiotic is polymyxin B.
11. 1. A method of killing a microorganism, the method comprising administering to the microorganism a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form comprising: a) a cationic surfactant which is a cetyltrimethylammonium halide; b) a chelating agent which is diethylenetriaminepentaacetic acid (DTPA); and c) Solvent wherein the pharmaceutical composition does not include chlorhexidine.
12. The method of claim 11 , wherein the microorganism is a bacterium.
13. The method of claim 11 , wherein the microorganism is a virus.
14. 12. The method of claim 11, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium bromide.
15. 12. The method of claim 11, wherein the cetyltrimethylammonium halide is cetyltrimethylammonium chloride.
16. 12. The method of claim 11, wherein the cationic surfactant is present at a concentration of about 1 mM to about 500 mM.
17. The method of claim 11 , wherein the solvent comprises ethanol.
18. The method of claim 11 , wherein the solvent comprises an organic solvent and an aqueous solvent.
19. 19. The method of claim 18, wherein the organic solvent is propylene glycol and the aqueous solvent is water.
20. 19. The method of claim 18, wherein the organic solvent is dimethyl sulfoxide and the aqueous solvent is water.
21. The method of claim 11 , wherein the microorganism is a fungus.
22. 12. The method of claim 11, wherein the microorganism is drug resistant.
23. 12. The method of claim 11, wherein the microorganism is multidrug resistant.
24. 12. The method of claim 11, wherein the microorganism is on the surface of the produce.
25. 25. The method of claim 24, wherein the agricultural product is a plant.
Citation Information
Patent Citations
Magnetic recording and reproducing device
JP1984011562A
Bactericidal compositions and methods of making and using the same
JP2007510712A
